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Epilepsy, a chronic neurological disorder has an estimated prevalence of between 0.4% and 
1.0% globally, and 1% in South Africa. Epilepsy has multiple underlying causes including head 
injuries, vascular insults, hippocampal sclerosis, cortical dysgenesis, drug or alcohol abuse and 
infectious diseases, such as neurocysticercosis and HIV/AIDS. Causes in South Africa are 
likely to be infectious due to the high HIV and tuberculosis prevalence. The condition has 
substantial individual and societal economic impacts, with economic costs ranging from the 
direct and indirect costs of treatment and loss of productivity due to illness. Primary treatment 
of epilepsy in the South African public sector is through pharmacotherapy, with monotherapy 
being preferred to polytherapy. No cost-effectiveness studies on the first-line treatment of 
epilepsy have been conducted in the South African context or in similar contexts using the 
combination of drugs in this analysis which are levetiracetam, lamotrigine, carbamazepine, 
phenytoin and valproate. The current first-line epilepsy treatment in South Africa is 
lamotrigine, phenytoin or carbamazepine. Levetiracetam is under consideration for use as a 
first-line treatment due to the reported minimal serious side effects, its ease of use, linear 
pharmacokinetics and reduced interaction with other drugs. 
The study was model-based and conducted from the providers’ perspective, specifically in the 
South African public health sector. It compared levetiracetam, lamotrigine, carbamazepine, 
phenytoin and valproate as first-line treatment in focal seizures (International Classification of 
Diseases (ICD)-10 code: G40.2) and generalized tonic-clonic seizures (ICD-10 code: G40.3). 
The population considered for the analysis was patients with newly diagnosed epilepsy 
expected to utilize services in the public health sector. The analysis consisted of a cost-
effectiveness analysis and a budget impact analysis. The budget impact analysis was conducted 
for the first year of treatment for each of the treatment strategies, while the cost-effectiveness 
analysis was conducted for a five-year period. Both a decision-tree representing the first six 
months of treatment and a Markov model representing the rest of the treatment period were 
used for the cost-effectiveness analysis. The methodology for the cost-effectiveness analysis 
was based on the International Decision Support Initiative (IDSI) reference case. Costs were 
expressed as South African Rands, 2018 value and effects were expressed as Quality Adjusted 
Life Years (QALYs). Results were expressed as Incremental Cost-Effectiveness Ratios 
(ICERs) and sensitivity analyses were performed to cater for uncertainty. 
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The use of levetiracetam along with the use of phenytoin, valproate and carbamazepine in the 
treatment of newly diagnosed epilepsy was found to be dominated by treatment using 
lamotrigine. Treatment with lamotrigine over a five-year period was found to be the least costly 
option and had the highest number of QALYs gained. The estimated cost of treating one case 
of epilepsy was R1 252 higher using levetiracetam compared to using lamotrigine. 
Levetiracetam had 0,02 QALYs lower than those of lamotrigine. Phenytoin, carbamazepine 
and valproate were found to have the same effect size of 3,97 QALYs. 
Sensitivity analyses were conducted using some levetiracetam-related costs and quality of life 
values. Both the levetiracetam-related costs used in the sensitivity analyses showed that lower 
cost values were associated with less negative ICER values (i.e. levetiracetam became 
comparatively more cost-effective as the levetiracetam-related costs became lower). There 
were no trends observed regarding the impact of the quality of life measures and the probability 
of remaining controlled on levetiracetam on the ICER values obtained. 
The pharmaceutical costs of treating newly diagnosed epilepsy with levetiracetam were found 
to be higher in comparison to those of comparators. For a 100% treatment coverage, the cost 
of treatment with lamotrigine, the other second-generation AED under analysis was about R19 
million cheaper compared to treatment with levetiracetam over a one-year period. Treatment 
with carbamazepine was found to be the cheapest option, costing about R20 million less than 
treatment with levetiracetam. On inclusion of other health systems costs associated with seizure 
and side-effect treatment levetiracetam was still found to be the costliest treatment option while 
lamotrigine became the least costly option.  
The effect sizes of all the treatments under analysis were similar, with a difference of 0,04 
QALYs being observed between the most effective and the least effective treatment option. 
This led to costs being the main driver of the resulting ICER values. Approximately a 93% 
price reduction is required for levetiracetam to be more cost-effective than lamotrigine. The 
model results for the cost-effectiveness analysis agree with the findings from the study 
conducted to inform the National Institute for Health and Clinical Excellence (NICE) treatment 
guidelines in the United Kingdom, which found that levetiracetam was not cost-effective. 
Lamotrigine is recommended for the treatment of both partial and generalized tonic-clonic 
seizures by the Health Technology Assessment Agencies in the United Kingdom and Scotland. 
It is the only drug recommended for the treatment of both indications, with carbamazepine 
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being recommended for the treatment of partial seizures and valproate for the treatment of 
generalized tonic-clonic seizures. 
Levetiracetam was found to not be a cost-effective treatment option for both generalized tonic-
clonic seizures and partial seizures in the South African public health sector context, even when 
accounting for the titration period and the drug prevalence of Steven Johnson Syndrome 
associated with some of the comparators. Lamotrigine is therefore recommended for use as the 
first-line treatment of epilepsy in the South African public health sector. 
ACKNOWLEDGEMENTS 
Vimbayi Mafunda and Thomas Wilkinson are acknowledged for their assistance, supervision 
and guidance in the development of this project. Members of the Health Economics Unit at the 
University of Cape Town for their technical support in the carrying out of this project. I would 
also like to acknowledge the contributions by the National Essential Medicines List Committee 
in the development of the research protocol for this study and technical support throughout the 
development of this project. 
My deep and sincere gratitude to my family for the financial and emotional support provided 
throughout this period. Thank you for always believing in me and allowing me to follow my 
dreams. I would also like to thank my friends for all the encouragement and providing 
distractions when needed. 
vi 
Table of Contents 
Plagiarism declaration ............................................................................................................. ii 
Thesis abstract ......................................................................................................................... iii 
Acknowledgements .................................................................................................................. v 
Table of figures ....................................................................................................................... vii 
Table of tables ....................................................................................................................... viii 
Abbreviations .......................................................................................................................... ix 
Part A: Research Protocol 
 Aims and research question .................................................................................................... 1 
 Literature review ..................................................................................................................... 2 
 Methodology ......................................................................................................................... 13 
 Ethics considerations ............................................................................................................ 19 
 References ............................................................................................................................. 19 
 Appendices ............................................................................................................................ 23 
Part B: Structured literature review 
Objectives of the literature review ......................................................................................... 1 
Use of economic evaluations in the health sector .................................................................. 1 
Selection process for medicines for use in the South African public health sector ............... 8 
Background information on epilepsy ..................................................................................... 9 
Review of economic evaluations for pharmacotherapy in epilepsy ..................................... 17 
References ............................................................................................................................ 30 
Part C: Journal Manuscript 
Title page ................................................................................................................................ 1 
Abstract .................................................................................................................................. 2 
Introduction ............................................................................................................................ 5 
Methods .................................................................................................................................. 8 
Results .................................................................................................................................. 19 
Discussion ............................................................................................................................ 23 
vii 
 Conclusion ............................................................................................................................ 26 
Limitations ........................................................................................................................... 27 
References ............................................................................................................................ 27 
Part D: Appendices to the dissertation
 Letter of approval from UCT HREC ...................................................................................... 1 
 Instructions to author (BMJ) ................................................................................................... 3 
Part E: Policy Brief 
 Executive summary ................................................................................................................. 1 
 Introduction ............................................................................................................................. 2 
 Research objective .................................................................................................................. 5 
 Methods................................................................................................................................... 6 
 Findings................................................................................................................................... 8 
 Conclusion ............................................................................................................................ 10 
 Policy recommendations ....................................................................................................... 11 
 References ............................................................................................................................. 12 
Table of figures 
Part A: Research Protocol 
Figure 1: The cost-effectiveness plane and decision-making. ................................................... 5 
Figure 2: Structure of the decision tree model. ........................................................................ 13 
Figure 3: Structure of the Markov model for analysis ............................................................. 14 
Part B: Structured literature review 
Figure 1: The cost-effectiveness plane and decision-making. ................................................... 6 
Part C: Journal Manuscript 
Figure 1: Decision-tree model for the first 6 months of treatment. ........................................... 9 
Figure 2: Structure of the Markov model. ............................................................................... 11 
Figure 3: Framework to estimate budget impact of introducing levetiracetam to the South 
African public health system for the treatment of epilepsy. .................................................... 12 
viii 
 
Figure 4: Cost-effectiveness plane for the first-line treatment of epilepsy with levetiracetam.
.................................................................................................................................................. 20 
Figure 5: Tornado plot for sensitivity analyses........................................................................ 21 
Part E: Policy Brief 
Figure 1: Comparison of costs and effects of the treatment options. ......................................... 9 
Figure 2: Comparison of the total cost to the health system of treatment using the drugs under 
analysis. .................................................................................................................................... 10 
 
Table of tables 
Part A: Research protocol 
Table 1: Summary of the IDSI reference case principles. ......................................................... 4 
Table 2: Treatment options for newly diagnosed epilepsy under the South African Standard 
Treatment Guidelines. ................................................................................................................ 8 
Table 3: Cost-effectiveness analyses on the first-line treatment of epilepsy. .......................... 11 
Table 4: Summary of recommendations by HTA agencies. .................................................... 12 
Part B: Structured literature review 
Table 1: A comparison of the types of economic evaluations ................................................... 2 
Table 2: Treatment options for newly diagnosed epilepsy under the South African Standard 
Treatment Guidelines . ............................................................................................................. 13 
Table 3:Clinical effectiveness or efficacy of levetiracetam in the treatment of newly 
diagnosed epilepsy. .................................................................................................................. 15 
Table 4: A summary of identified cost-minimization studies. ................................................. 19 
Table 5: A summary on the cost-effectiveness studies identified. ........................................... 25 
Part C: Journal Manuscript 
Table 1:  Key clinical inputs. ................................................................................................... 13 
Table 2:  Utility values for each Markov state. ........................................................................ 14 
Table 3: Utilization rates for services. ..................................................................................... 14 
Table 4: Cost Inputs for the models . ....................................................................................... 15 
Table 5: Per patient cost of treating Steven-Johnson Syndrome. ............................................ 16 
Table 6: Pharmaceutical costs associated with each treatment regimen. ................................. 17 
ix 
 
Table 7: Pharmaceutical costs over titration period ................................................................. 18 
Table 8: Calculations for costs associated with the Markov Model. ....................................... 18 
Table 9: Summary of the cost-effectiveness results for the first-line treatment of epilepsy 
using levetiracetam. ................................................................................................................. 19 
Table 10: Values used for the decision-tree sensitivity analyses. ............................................ 20 
Table 11: ICERs obtained from sensitivity analyses. .............................................................. 20 
Table 12: Calculation for the estimated population of interest ................................................ 21 
Table 13: Budget Impact Analysis for pharmaceutical costs in first line treatment of epilepsy.
.................................................................................................................................................. 22 
Table 14: Budget Impact Analysis sensitivity analysis for the cost of levetiracetam in the 
first-line treatment of epilepsy. ................................................................................................ 22 
Table 15: Non-pharmaceutical costs associated with the treatment of epilepsy. .................... 22 
Table 16: Budget Impact Analysis for health systems costs from the providers’ perspective in 





 AED – Antiepileptic Drugs 
 CBZ – Carbamazepine 
 CEA – Cost-Effectiveness Analysis 
 CLB- Clobazam 
 GBP – Gabapentin 
 HR – Hazard Ratio 
 HRQoL – Health-related Quality of Life 
 ICER – Incremental Cost-Effectiveness Ratio 
 LEV – Levetiracetam 
 LMICs - Low and Middle-Income Countries 
 LTG – Lamotrigine 
 OXC – Oxcarbazepine 
 PB- Phenobarbitone 
 PHT – Phenytoin 
 QALY – Quality Adjusted Life-Year 
 QoL – Quality of Life 
 TPM – Topiramate  
 VPA – Valproate 









A cost-effectiveness analysis and budget impact of levetiracetam 
compared to other available epilepsy pharmacotherapy treatments in the 
South African public health sector. 
Aim 
To establish the cost-effectiveness and budget impact of levetiracetam compared to 
lamotrigine/carbamazepine/phenytoin/valproate as first line treatment for newly diagnosed 
epilepsy patients in the South African public health sector. 
Research question 
What is the cost-effectiveness and budget impact of levetiracetam compared to standard care 
(lamotrigine/carbamazepine/phenytoin/valproate) as first line treatment for epilepsy in the 
South African public health sector? 
The population considered for the cost-effectiveness analysis will be patients with newly 
diagnosed epilepsy in need of first-line treatment in the South African public sector (1). 
Although there are multiple algorithms for the treatment of epilepsy in multi-morbid patients 
and the possibility of moving to second-line treatment in cases where there is treatment failure, 
this analysis will solely focus on the use of the above stated drugs in first-line treatment 
regardless of co-morbidities. The study will focus on the treatment of focal seizures 
(International Classification of Diseases (ICD)-10 code: G40.2) and generalized tonic-clonic 
seizures (ICD-10 code: G40.3). Results will be presented as costs and effects. Cost will be 
expressed as South African Rands, 2018 value and will be calculated from the perspective of 
the South African government. Outcomes will be expressed as Quality Adjusted Life Years 
(QALYs). Each of the five treatment options will be considered as mutually exclusive, 
different, independent strategies for the analysis and will be compared to each other. A budget 
impact analysis will be carried out to inform considerations of affordability from a public-








Background on economic evaluations 
Economic evaluations are essential in the health sector decision-making process in order to 
maximize the benefits obtained from the available resources to society, minimizing opportunity 
costs (2). This is especially important in the context of low and middle-income countries 
(LMICs) where opportunity costs of public health programs can be high relative to other 
needed services in competing sectors (2). The spiralling increase in healthcare costs and the 
continued development of medical technology has contributed to the need for economic 
evaluations in health-related decision-making. An economic evaluation is defined as the 
comparative analysis of two or more alternative courses of action in terms of both their costs 
and effects (3). Full economic evaluations include; cost-utility analysis (CUA), cost-
effectiveness analysis (CEA) and cost-benefit analysis (CBA) (3). A CEA will be performed 
for this study and it is defined as an analysis whereby costs are related to a single, common 
effect that may differ in magnitude between the alternative interventions (3). CEAs measure 
both allocative and technical efficiency in the allocation of resources (4). The methodology for 
the CEA section of this study will be based on the International Decision Support Initiative 
(IDSI) reference case (5) which provides a technical guide for economic evaluations. The 
reference case consists of eleven principles which are transparency, comparators, evidence, 
study perspective, measure of health outcomes, costs, time horizon and discount rate, 
heterogeneity, uncertainty, constraints and equity considerations (5).  
 
Principle Description 
Transparency -Requires declaration of all interests by analysts, acknowledgement of 
limitations to the study and a full and accurate description of the decision 
problem to be reported (5). 
Comparators -Current practice in the context of the decision problem must be used as 
comparators in the analysis. 
-Where possible the best supportive, non-interventional care must be included 
as a comparator (5). 
Evidence -A transparent, systematic approach in obtaining evidence must be used (5).  
-Estimates of the clinical effects should be informed through a systematic review 





-Must be determined prior to the economic evaluation to ensure that data 
collected is appropriate.  
-Three possible perspectives for an analysis are; providers’ perspective, 
patients’ perspective and the societal perspective.  
-Societal perspective should be used in an economic evaluation where possible.  
-Requires analysis to reflect direct costs and health outcomes for the chosen 




-A CEA allows for the measurement of both morbidity and mortality, giving a 
broader measure of the health outcomes (4). 
-QALYs and Disability Adjusted Life Years (DALYs) are commonly used as 
multi-dimensional outcomes (4).  
-Disease specific measures, for example seizure control in epilepsy, can also be 
used as outcome measures (4). 
- The IDSI reference case requires a detailed, transparent description of the 
method used in calculating the chosen outcome measures for the analysis (5). 
Measure of 
Costs 
-Involves the identification, quantification and valuation of all resources used in 
the implementation of a given health intervention (6). 
 -Costs are measured in monetary terms and are determined by the study 
perspective (4). 
-The IDSI reference case requires the analysis to include costs that where not 
incurred in the study settings for trial-based studies but which are likely to be 
incurred if the intervention is to be rolled out (5).  
-Analysis should also include estimates of changes in costs due to economies or 




- Time horizon is the duration over which the health outcomes and costs for the 
study will be calculated (7). 
-In principle, it should be the period over which the costs and/or effects of the 
treatment options under analysis are expected to differ and often a patients’ 
lifetime is used to fully capture these differences (3). 
- The same time horizon must be used for both costs and effects (7). 
- Discounting is the adjustment of the value of costs and effects incurred in 
future (over a year after the initiation of the intervention) in order to demonstrate 
time preference (8).  
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-The IDSI reference case requires the use of a 3% annual discount rate for both 
costs and effects, with additional analyses exploring different rates, including an 
annual discount rate reflecting the rate for government borrowing (5).  
Heterogeneity -Refers to heterogeneity of the population under analysis.  
-Should be considered in population subgroups whereby the characteristics of 
the different populations may influence the absolute health effect, or the costs 
associated with the intervention (5).  
-The IDSI reference case requires subgroup analysis to be determined by the 
evidence base and whether the differences between the populations have an 
important influence on costs and effects (5). 
Constraints -The IDSI reference case requires that financial constraints be explored through 
a budget impact analysis.  
-The budget impact analysis should estimate the implications of implementing 
the intervention using approximations of disease prevalence and numbers in 
need of the intervention (5).  
-Budget impact analysis should also reflect the decision problem and the 
constituency in which the intervention will be used (5). 
Uncertainty -Can be due to the generalization of results from research settings to other 
settings, extrapolation of data, sampling of data or choice of analytic method  
(9).  
-Sensitivity analysis is used in economic evaluations to cater for uncertainty.  
-Three types of sensitivity analyses can be used; simple sensitivity analysis, 
probabilistic sensitivity analysis and threshold analysis.  
-The IDSI reference case requires that economic evaluations explore all possible 
sources of uncertainty where feasible (5). 
Equity 
Considerations 
-The IDSI reference case requires the use of an appropriate mechanism for the 
assessment of equity implications regarding an intervention based on the 
decision problem (5).  
-There is need for consideration of equity implications at all stages of the 
evaluation (5). 
Table 1: Summary of the IDSI reference case principles. 
The decision rule for economic evaluations, specifically CEAs is based on the ICER values 
obtained. If the ICER of an intervention is equal to or less than a given threshold that represents 
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“willingness-to-pay”, the intervention is considered “cost-effective” and therefore worth 
implementing (4). The ICERs obtained from an analysis can be plotted on a cost-effectiveness 
plane as shown in figure 1. 
 
Figure 1: The cost-effectiveness plane and decision-making. 
 
Background on Epilepsy 
Epilepsy is a chronic neurological condition associated with considerable morbidity and 
mortality globally (10). Epilepsy is characterized by recurrent unprovoked seizures, which are 
brief episodes of involuntary movements and is associated with excess morbidity and mortality, 
which have been found to be higher in LMICs compared to high income countries (11)(12). 
Causes of epilepsy-related mortality range from direct causes such as sudden unexpected death 
in epilepsy (SUDEP) and status epilepticus, and indirect causes such as suicides and 
complications of antiepileptic drugs (13). Seizures are classified based on their origin in the 
brain (14). Focal seizures originate in a network localized in one brain hemisphere and may or 
may not lead to the loss of consciousness (14). Focal seizures can spread to the rest of the brain, 
resulting in a generalized seizure (secondary generalization) (10). Generalized seizures rapidly 
engage networks from both sides of the brain and range from brief absence attacks to major 
convulsions (10). Seizures can also have an unknown origin (14). Epilepsy has multiple 
6 
 
underlying causes including head injuries, vascular insults, hippocampal sclerosis, cortical 
dysgenesis, drug or alcohol abuse and infectious diseases, such as neurocysticercosis and 
HIV/AIDS (15)(10). Common causes of epilepsy in South Africa are likely to be infectious 
(15).  
Epilepsy, a chronic neurological disorder has an estimated prevalence of between 0.4% and 
1.0% globally, and 1% in South Africa (12)(16). The prevalence of epilepsy is two to three 
times higher in LMICs compared to high income countries (11). Prevalence is also higher in 
rural areas within the LMICs compared to urban areas (11). The 2013 global burden of disease 
study identified uncontrolled epilepsy as one of the diseases associated with a high disability 
weight (17). Half of the burden attributed to epilepsy is estimated to be due to morbidity, while 
the other half is due to mortality, signifying the importance of quality of life with regards to 
the treatment of epilepsy (11). Studies conducted in LMICs suggest that mortality rates are 6 
to 9 times higher among people with epilepsy compared to the general population and an 
increased age-standardized mortality rate of 2 to 3 times that of the general population has also 
been observed (11). A significant proportion of the burden caused by epilepsy in developing 
countries can be averted through scaling up the routine availability of cost-effective treatment 
(18). Epilepsy also has social implications for individuals living with the disease which 
contributes to a lower quality of life (11). This includes high levels of stigma especially in the 
African context whereby it is believed that epilepsy is a result of a curse and is a contagious 
condition in some social circles (11). Epilepsy is also an economic problem, with economic 
costs ranging from direct and indirect costs of treatment and loss of productivity due to illness 
(11). A relationship between epilepsy prevalence and social deprivation has also been found 
(10). 
Epilepsy is mostly treated using anti-epileptic drugs (AEDs). The epilepsy treatment gap is 
defined as the difference between the number of people with active epilepsy and the number 
of people whose seizures are adequately suppressed, expressed as a percentage (11). The 
treatment gap has been found to be higher in LMICs compared to high income countries, and 
in rural areas compared to urban areas (11). In LMICs the treatment gap is about 75% due to 
multiple factors (12). These factors include lack of skilled health care professionals and the 
unavailability of AEDs in the health system, the inability of patients to access health facilities, 
high treatment costs and misconceptions of the causes of epilepsy and fear of stigmatization 
(11). At least 25% of epilepsy patients continue to have seizures despite optimal treatment with 
one or more AEDs due to lack of efficacy of available drugs or treatment limitations due to 
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side effects (14). AEDs can be classified into first- and second-generation drugs. Phenytoin, 
valproate and carbamazepine are first-generation, while lamotrigine and levetiracetam are 
second-generation AEDs. Second-generation AEDs have been found to generally have better 
tolerability, improved safety profiles and fewer drug interactions compared to first-generation 
AEDs (14). Levetiracetam is under consideration for inclusion on the South African Essential 
Medicines List due to its favourable side-effect profile and minimal drug interactions. This is 





















Comparison of anti-epileptic agents 
Table 2: Treatment options for newly diagnosed epilepsy under the South African Standard Treatment Guidelines (19). 
Drug Dose Mechanism of Action Indications Adverse Effects 
Lamotrigine Initially 25mg daily for 2 weeks, 
then 50mg daily for 2 weeks, 
thereafter increase by up to 50-100 
mg every 1-2 weeks according to 
response. Usual maintenance dose is 
100-200 mg/day up to 500mg/day as 
required. 
Inhibition of the release 





Monotherapy or add-on therapy for focal 
epilepsy with or without secondary 
generalized tonic-clonic seizures and in 
primary generalized tonic-clonic 
seizures; adjunctive therapy for children, 
and for Lennox-Gastaut syndrome. Also 
registered for bipolar affective disorder. 
Maculopapular rash manifesting within 4 
weeks of initiating treatment, which 
occasionally progresses to severe 
generalized hypersensitivity reactions such 
as Steven-Johnson syndrome. 
Carbamazepine Initially 100-200 mg twice daily, 
with increments of 100-200 mg/day 
at weekly intervals according to 
seizure control and adverse effects 
Sodium channel 
blockade. 
First-line management of generalized 
and focal seizures but not effective in the 
treatment of absence seizures or atonic 
seizures. 
Sedation, ataxia, gastrointestinal effects. 
Side effects may subside spontaneously 
after 7-14 days’ treatment, or with dose 
reductions. 
Valproate Initially 600mg/day in divided 
doses, increase by 200mg/day at 3-
day intervals until control is 
achieved. Maximum 2.5g/day 
Unknown All forms of epilepsy. Also used as 
prophylaxis for migraines and for 
control of the acute manic phase of 
bipolar disorder. 
Gastrointestinal effects, dose-related CNS 
effects such as fatigue and sedation, ataxia 
and dysarthria. Teratogenic in pregnancy, 
classified as a category D drug. 
Phenytoin Initially 150-300 mg daily, after 5-
20 days small increments may be 
made if required. Maintenance 
range: 5-7mg/kg/day. 
Unknown All forms of epilepsy except absence and 
myoclonic seizures. Also used in status 
epilepticus. 
Related to plasma levels. Nausea, 
vomiting, tremor, ataxia, nystagmus and 
speech disturbances. Category D drug in 
pregnancy due to increased risk of foetal 
abnormalities. 
Levetiracetam Initially 250 mg twice daily, 
increasing to initial therapeutic dose 
of 500mg twice daily. Adjust 
according to need with 500 mg 
twice daily every 2-4 weeks. 
Maximum dose 3g/day 
Unknown Mono- or add-on therapy for focal 
seizures in patients from 16 years of age. 
Add-on therapy for primary generalized 
tonic-clonic seizures from 16 years of 
age. Add-on therapy for myoclonic 
seizures in adults and adolescents from 
12 years of age. 
Somnolence, fatigue, dizziness. Infrequent 




Comparative clinical effectiveness of levetiracetam 
The Komet study (2013) found that time to withdrawal from treatment was not significantly 
different between levetiracetam and the standard AEDs valproate and carbamazepine for newly 
diagnosed epilepsy (20). A study by Brodie et al. (2007) found that levetiracetam and 
controlled-release carbamazepine produced equivalent seizure freedom rates in newly 
diagnosed epilepsy patients at optimal dosing in a setting mimicking clinical practice (21). No 
conclusive evidence on the superiority of levetiracetam in the treatment of newly diagnosed 
epilepsy was found (22). 
Comparative costs of AEDs 
The acquisition costs of second-generation AEDs as a therapeutic class are higher than those 
of first-generation AEDs, but their use in clinical practice is justified due to an observed higher 
rate of seizure control compared to first-generation AEDs (23). 
Cost-effectiveness analyses for the treatment of epilepsy using AEDs 
Various studies have been conducted to determine the cost-effectiveness of some of the drugs 
under analysis, below is a summary of some the studies which have been identified. A study 
conducted in the WHO developing subregions comparing first generation AEDs found that 
phenytoin and phenobarbitone were the most cost-effective treatment options compared to 
carbamazepine and valproate (18). A study comparing treatment strategies for first- and 
second-line treatment for newly diagnosed epilepsy found the use of carbamazepine followed 
by valproate as second-line treatment to be the most cost-effective option (1). Most of the 
studies identified were carried out in Europe, limiting their applicability in the South African 
setting due to differences in economic status, quality of life and availability of resources. Both 
trial-based and model-based studies were identified and the study perspective for the studies 




Author Study Setting and 
population 
Perspective Intervention and 
comparators 


























Model-Based using a 
Markov model with 
three possible states; 
healthy and susceptible 








DALYs lost ICERs for all treatment 
options were calculated 
relative to the “Do Nothing 
Approach”. 
-ICER range for PHT and PB: I$ 800 – I$ 
2,000 per DALY averted. 
-Average ICER range for CBZ and VPA:  
I$ 1,100–3,000 per DALY averted. 






-Data on treatment 
effects was obtained 
from literature. 
- Studies included 
had a study 
population of 
patients ≥12 years 
with newly 
diagnosed epilepsy. 





-CBZ followed by 
LTG as second 
line treatment 
-CBZ followed by 
VPA as second 
line treatment 
-LTG followed by 
CBZ as second 
line treatment 
-LTG followed by 
VPA as second 
line treatment 
-VPA followed by 
CBZ as second 
line treatment 
-VPA followed by 
LTG as second 
line treatment 
Model-based using a 
decision tree with three 
outcome groups; 
complete success, 





Euros (€) -Complete success 
(defined as a patient 
being seizure free) 
-Partial Success 
(defined as a reduction 
in seizure rate by at 
least 50%) 
-Failure (defined as 
inadequate seizure 




ICERs were calculated 
relative to the previous less 
costly option. CBZ followed 
by VPA as second line 
treatment was used as the 
reference treatment since it 
was the least costly. 
-The ICER of CBZ followed by LTG 
relative to the CBZ followed by VPA 
strategy was €6,079 per additional 
complete success patient. 
-The ICER of LTG followed by VPA 
relative to CBZ followed by VPA was 
€40,422 per additional complete success 
patient. 
-CBZ followed by VPA as second line 
treatment was found to be the most cost-
effective strategy. 
-Use of LTG as second-line treatment was 
found to likely be the most cost-effective 
option in a case were willingness to pay 
was more than €6000 for an additional 
complete success patient. 







Patients in India with 
newly diagnosed 











For each of the 
first-line 
treatment options 
CLB was used as 
Model-based analysis 
using a decision-tree 
model with two 
outcomes; complete 







-Complete success  
-Failure of seizure 
control 
ICER was calculated relative 
to the previous less costly 
option. CBZ followed by the 
addition of CLB was used as 
the reference treatment since 
it was the least costly. 
-The ICER for TPM with CLB as add on 
therapy was US$ 764,98 per additional 
patient with complete success. 
-The LEV with CLB as add on therapy was 
the costliest treatment strategy.  
-The strategies containing PHT, VPA and 
OXC as first-line treatment were 
dominated. 
-TPM with CLB as add on therapy was 
found to be a cost-effective strategy.  
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add on therapy in 
the case of 
treatment failure 
in the first six 
months of 
treatment. 
-The study concluded that the use of TPM 
alone, followed by CLB as add on therapy 
was more cost-effective compared to CBZ 
alone followed by CLB as add-on therapy, 






-Patients ≥5 years in 
the United Kingdom 














Trial-based study -2-year time 
horizon 
-3.5% for costs 
Pounds (£) -QALYs gained 
-seizures avoided 
ICER was calculated relative 
to the previous less costly 
option and not based on a 
baseline. 
CBZ was considered as the 
standard treatment. 
-Economic analysis supported the use of 
LTG over CBZ in terms of both cost per 
seizure avoided and cost per QALY gained. 
-Results did not support the use of GBP or 
TPM over the standard treatment of CBZ. 
-Uncertainty with regards to the 
comparison of CBZ and OXC. 
Marson et 
al. (2007)  
(24) 
Arm B 
-Patients ≥5 years in 
the United Kingdom 








Trial-based study -2-year time 
horizon 
-3.5% for costs 
Pounds (£) -QALYs gained 
-seizures avoided 
ICER was calculated relative 
to the previous less costly 
option and not based on a 
baseline. 
VPA was considered as the 
standard treatment. 
 
-Economic analysis based on cost per 
seizure avoided supported that VPA should 
remain the first-choice drug for idiopathic 
generalized or unclassified epilepsy.      
-The cost per QALY analysis suggests that 
there is a high probability that TPM is a 
cost-effective alternative to VPA 
Table 3: Cost-effectiveness analyses on the first-line treatment of epilepsy. 
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Recommendations by HTA agencies 
Institution Recommendations 
National Institute for Health 
and Clinical Excellence 
(NICE) (2012) 
 
-First-line treatment in patients with newly diagnosed epilepsy with focal seizures 
is either carbamazepine or lamotrigine (25). 
- First-line treatment in patients with newly diagnosed epilepsy with generalized 
tonic-clonic seizures is valproate, with lamotrigine as an option for patients who 
cannot be given valproate (25). 
- Levetiracetam was not cost-effective at the June 2011 unit costs which were used 
to inform the treatment guidelines and is only offered as adjunctive therapy to 
patients with generalized tonic-clonic seizures (25). 
Canadian Agency for Drugs 
and Technologies in Health 
(CADTH) (2011) 
-Pharmacological monotherapy is recommended for the treatment of newly 
diagnosed epilepsy with no drug specifications for each diagnosis (26).  
- Conducted a study on the safety and cost-effectiveness of levetiracetam in the 
treatment of epileptic patients which was non-conclusive regarding the cost-
effectiveness of levetiracetam (26).  
Scottish Intercollegiate 
Guidelines Network (SIGN) 
(2018) 
 
-Lamotrigine is preferred to carbamazepine for the treatment of focal epilepsy (27). 
-Guidelines acknowledge the presence of clinical trial evidence that levetiracetam 
can also be used as monotherapy for the treatment of focal epilepsy (27). 
- Lamotrigine and sodium valproate are recommended for the treatment of genetic 
generalized epilepsy (27). 
- Levetiracetam is recommended as first-line treatment in some instances, for 
example in women of reproductive age (27). 
Table 4: Summary of recommendations by HTA agencies. 
No cost-effectiveness studies on the first-line treatment of epilepsy have been conducted in the 
South African context or in a similar context using the combination of drugs under analysis. 
Current first-line epilepsy treatment in South Africa is lamotrigine, phenytoin or 
carbamazepine (28). There is need to determine the cost-effectiveness of all the available 
options for AEDs in South Africa due to the vast healthcare needs related to the quadruple 
burden of disease, scarcity of resources and the demand for efficient use of finances. 
Interventions implemented into the healthcare sector must be effective, both clinically and 
economically to ensure access, availability and acceptability of the interventions to patients 
(23). Some countries are estimated to spend as much as 1% of their total national health care 
expenditure on epilepsy care and treatment (11). This demonstrates the high healthcare 
expenditure associated with epilepsy treatment, solidifying the need for evidence-based 
decision making to maximize the efficient use of resources. Although there is not enough 
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evidence of a greater effectiveness of levetiracetam in the treatment of newly diagnosed 
epilepsy, the infrequency of serious side effects, its ease of use, linear pharmacokinetics and 
lack of interactions with other drugs justifies the need for this analysis (22). Some AEDs such 
as lamotrigine may cause hypersensitivity reactions in susceptible patients which can be serious 
for example in the case of Steven-Johnson Syndrome (29). An estimated incidence of 
hypersensitive reactions from AEDs ranges from 1 per 1000 to 1 per 10 000 users (29). Reports 
have shown carbamazepine, phenytoin, phenobarbitone, and lamotrigine to be connected to 
hypersensitivity reactions (29). 
Methodology 
Study design 
A cost-effectiveness analysis evaluating first-line treatment strategies in adult patients (18 
years and over) with newly diagnosed epilepsy will be conducted along with a budget impact 
analysis for each possible treatment strategy. A providers’ perspective, specifically in the 
public sector will be adopted for the economic evaluation. A cost-effectiveness analysis will 
be conducted for the first six months of treatment and will be extended to a five-year period. A 
decision tree will be used for the analysis over the first six months of treatment and a Markov 
model will be employed to extend the analysis to a five-year period. Microsoft excel will be 
used to create both the decision tree and the Markov model. 
Decision Tree 
A decision tree will be used for the five available treatment strategies with the following 
outcomes; “controlled on treatment”, “controlled off treatment” and “uncontrolled”. A 
controlled patient will be defined as one who is seizure-free from onset of treatment to the end 
of the six-month period. The decision tree will represent costs and effects for the first six 
months of treatment. 
 
 




The Markov Model will be used to calculate costs and outcomes for the five-year period. Each 
Markov state will have a health outcome and cost associated with it (30). Transition 
probabilities will be used to describe all possible movements between the Markov states and 
transitions will occur after each Markov cycle (30).  
Five iterations of the model will be evaluated based on the following treatment strategies; 
levetiracetam, lamotrigine, carbamazepine, phenytoin and valproate. The iterations will each 
have four Markov states; controlled on treatment, controlled off treatment, uncontrolled and 
dead. The uncontrolled state will represent the costs and health of all patients who have failed 
first-line treatment. The structure of the model is based on literature and will be validated 
through clinical expert opinion. Each state will have a health-related quality of life measure 
(HRQoL), which will be estimated from literature. Transition probabilities will be based on 
values obtained from the literature. The time horizon used will be five years and a cycle length 
of 6 months will be used to capture transitions between Markov states (23). Utilization rates of 
epilepsy-related services will be obtained from studies conducted in the South African context, 
and if none are found, values will be obtained from similar settings. A 3% annual discount rate 
on both the costs and the outcomes will be used in accordance with the requirements for the 
IDSI reference case (5).  
 
 





Decision model inputs 
Collection of data on effects 
Effectiveness parameters will be extracted from an unpublished systematic review conducted 
for the South African National Essential Medicines List Committee (NEMLC) (31). The 
remaining model parameters will be based on literature data. These include; service cost 
parameters, pharmaceutical costs, utility values and parameters to determine transition 
probabilities for the Markov model. The search will not be limited by date. A snowballing 
approach will be used to identify studies through checking the citations of relevant studies.  
Collection of data on costs 
Costs will be collected from available literature and secondary sources from a providers’ 
perspective. Costing items willing include; pharmaceutical costs, hospitalization costs and 
costs associated with the treatment of side-effects. Costs will be obtained from appropriate 
costing studies on epilepsy treatment and then adapted to the South African context using the 
following sources and where necessary expert opinion on clinical practice (32); 
 Uniform Patient Fee Schedule April 2018 for inpatient costs 
 Health Systems Trust Report, District Health Barometer (2017/2018) 
 National Health Laboratory Service State Price List for diagnostic costs 
 Single Exit Price and National contract circulars for the drug unit prices. 
Costs will be expressed as South African Rands (ZAR) in 2018 values.  
Review of epilepsy economic evaluations 
An iterative snowball search will be conducted to identify economic evaluations on the  
pharmacological treatment of epilepsy. Both trial-based and model-based evaluations will be 
included. The following inclusion criteria will be used 
 Studies in English looking at an adult population diagnosed with epilepsy; 
 Cost-effectiveness and cost-minimization studies on epilepsy treatment with one of the 
drugs of interest as either a comparator or an intervention; 






The following exclusion criteria will be used: 
 Studies considering seizures that are not identified as having a partial or generalized origin. 
 
A literature table will be used to record information obtained from the studies. 
Quality assessment strategy 
The Consensus on Health Economics Checklist Extended (CHEC-extended) will be used to 
determine the quality of economic evaluations included in the review (33). 
Data extraction 
The following will be extracted onto a data extraction sheet from the eligible studies: 
 Study identifiers, which will be authors’ names, study title, publication date, journal name, 
volume, issue, page numbers in publication and place of publication;  
 Setting or location of the economic evaluation; 
 Information on target population, including gender and age; 
 Comparators used in the study, time horizon of study, study perspective, discounting rate 
for both costs and effects if discounting is applied and type of modelling used if applicable; 
 Inflation rates (if applicable), reference year of study, data sources for both costs and 
effects; 
 Details on outcomes; 
 Details on cost-effectiveness results and sensitivity analyses. 
 
Cost-effectiveness analysis 
An analysis of the decision-tree will be conducted for the first six months of treatment. Costs 
and effects in the first six months of treatment will be obtained. The values obtained will be 
fed into the Markov model. 
The analysis of the Markov model will result in transition probabilities of a theoretical patient 
ending up in one of four Markov states; death, controlled on treatment, controlled off treatment 
and uncontrolled. Treatment outcomes will be extrapolated to effects over a five-year period 
in the form of QALYs. Based on the transition probabilities, the expected costs of the five 
treatment options over the five-year period will be determined. Based on this data collected, 
the interventions will be listed from least expensive to most expensive to determine if there are 
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any dominated strategies. ICERs will be calculated for the non-dominated strategies, using the 
previous less costly treatment strategy for comparison. The following formula will be used to 
calculate the ICER: 
ICER =  
(     )   (     )  ( )
(  )   (  )  ( )
 
Results will be presented in tabular form and on a cost-effectiveness plane.  
Budget impact analysis 
A budget impact analysis will be conducted for each of the five strategies from the providers’ 
perspective for the first year of treatment. The analysis will follow the Principles of Good 
Practice for ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 
(34) and will be conducted using Microsoft excel. The five strategies will be treated as mutually 
exclusive in the analysis. The target population for which the budget impact analysis will be 
conducted is adult patients with newly diagnosed epilepsy who have access to the South 
African public health sector. Population size will be determined through data obtained from 
literature on the prevalence, incidence, utilization rates and death rates related to epilepsy in 
South Africa where possible. If data specific to South Africa is not found, data from 
international sources or similar populations will be used. Unit costs will represent the annual 
healthcare costs of providing treatment for each patient for each strategy and will be calculated 
based on the direct costs of disease-related treatments and the direct costs of resources required 
for putting the intervention into effect (35). These resources will include medication, 
equipment and labour costs (35). Utilization rates will be multiplied by the target population. 
This value will be multiplied by the unit cost of providing each intervention to get the annual 
total expenditure for each strategy. Results will be presented in a table as the total costs of 
adopting each of the five treatment strategies. The computing framework and input data will 
be validated through expert consultation in the development phase and the verification of costs. 
Sensitivity analysis 
Sensitivity analyses will be conducted to address uncertainty. One-way sensitivity analyses for 
both the cost-effectiveness analysis and the budget impact analysis will be performed to cater 
for possible long-term changes in context in the South African public sector. The results will 




Benefit of study to the health system 
The results and recommendations from the study can be used in the decision-making process 
for determining the drugs to be included on the Essential Medicines List (EML) and Standard 
Treatment Guidelines for first line treatment of epilepsy in South Africa. Following a 
determination for listing on the EML, Provincial Departments of Health will consider whether 
and how levetiracetam should be used for the treatment of epilepsy. This study is likely to have 
a significant impact in the way in which the approximately 6 000 patients with newly diagnosed 
epilepsy in South Africa are treated in the public health system. The study will also add to the 
body of knowledge on the cost-effectiveness of the various available epilepsy 
pharmacotherapy, which is especially important in the context of the developing world where 
there is scarce research on this and a shortage of resources to conduct the required research. 
Conflict of interest 
No conflict of interest. 
Study limitations 
 The translation of the level of seizure control into a HRQoL value. 
 A systematic review of the literature on economic evaluations for epilepsy is preferred 
but will not be conducted due to resource limitation.  
 Some of the model parameters used will not be specific to the South African context. 
 Assumptions will be used in the modelling process which may not be representative of 
the heterogenous patterns seen in clinical practice. 
 There are no effectiveness studies directly comparing all the drugs under analysis, 
therefore data will be obtained through indirect comparison from multiple studies. 
 Analysis will not consider the impact of co-morbidities on the treatment of epilepsy. 
 
Research outputs/Dissemination of results 
 Policy Briefs 
 Engagement with policy makers through NEMLC 





There are no ethical considerations with regards to consent and privacy as the data used for the 
study will not contain any information which can result in the identification of participants, nor 
is the study proposing to involve any patient-level primary data collection. The study will 
adhere to the required international ethical standards, which will be confirmed through ethical 
approval by the relevant institutions. 
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I) Comparative clinical effectiveness of levetiracetam 

















 Patients ≥16 years of 
age with ≥2 
unprovoked seizures 
in the previous 2 
years and ≥1 in the 
previous 6 months 
 Patients were 
excluded if they had 
been treated with 
LEV, VPA or CBZ 
for any indication or 
treated for epilepsy 
with any other AED 
in the last 6 months 





trial with a 
two-parallel-
group design 










 Time to 
first 
seizure. 




LEV and standard 
AEDs. HR (95% 
CI) 0.90 (0.74 to 
1.08). 
 Time to first 
seizure was 
significantly 
longer for patients 
on standard AEDs 
compared to 
patients on LEV. 
HR (95% CI) 1.20 
(1.03 to 1.39). 
 LEV monotherapy 
was not superior to 
standard AEDs for 
the global 
outcome, namely 













 Adults with ≥2 
partial or generalized 
tonic–clonic seizures 
in the previous year 
 Exclusion criteria - 
pseudoseizures, 
seizures occurring 














trial with a per 
protocol 
analysis 















freedom rates in 
newly diagnosed 
epilepsy patients at 
optimal dosing in a 
setting mimicking 
clinical practice 
 Withdrawal rates 
were higher for 
CBZ (19.2%) 
compared to LEV 
(14.4%) 




II) Results for cost-effectiveness analysis 
Strategy Cost Effectiveness ICER 
1    
2    
3    
4    
5    
Table 2: Results for cost-effectiveness analysis for the five treatment strategies. 
 
III) Cost-effectiveness plot 
 
 

































IV) Results for budget impact analysis 
 
 Coverage (%) 100%  80%  50%  10% 
Coverage 
 (# of Patients) 
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Objectives of literature review 
 To obtain information on the use of economic evaluations in the health sector and the 
associated limitations. 
 To obtain information on the disease process of epilepsy, its economic and social 
impact and the available treatment options for the disease. 
 To obtain information on the overall status of epilepsy in South Africa. 
 To obtain information on the current epilepsy treatment practices in South Africa and 
the drug selection process for the Essential Medicines List. 
 To obtain information on economic evaluations that have been conducted on the use of 
monotherapy in the treatment of epilepsy. 
 To identify gaps in the literature and areas where further research is required. 
Use of economic evaluations in the health sector 
Economic evaluations aim to provide information on the efficiency of interventions, with 
efficiency being defined as the maximization of health benefits and the minimization of 
opportunity costs (1). This is especially important in the context of low- and middle-income 
countries (LMICs) where opportunity costs of public health programs can be high relative to 
other services needed in competing sectors (2). The spiraling increase in healthcare costs and 
the continued development of medical technology has contributed to the need for economic 
evaluations in health-related decision-making. An economic evaluation is defined as the 
comparative analysis of alternative courses of action in terms of costs and consequences (3). 
In the health sector, economic evaluations are used for the following purposes; to maximise 
benefits obtained from health care spending, to overcome regional variations in access, to 
develop clinical practice guidelines, to contain costs and manage demand and to provide 
bargaining power with suppliers of health care products (4). There are several types of 
economic evaluations which include; cost-minimization analysis (CMA), cost-effectiveness 




















Monetary Units Equal effects, therefore effects 
are not included in the analysis. 






Monetary Units Effects are measured in natural 
units. A single outcome of 
interest common to the 
interventions under analysis is 
identified. The outcomes for the 
interventions under analysis 
must be quantitatively different. 
 
Measurement of 
outcomes is not 
likely to be 
biased as data on 





Monetary Units Effects are in the form of a utility 
measure, usually “quality-
adjusted life-years” (QALYs) or 
“disability adjusted life-years” 
(DALYs). Single or multiple 
effects can be measured, they do 
not necessarily have to be 
common to all the alternatives 
under analysis. 









Monetary Units Effects are measured in 
monetary terms. Single or 
multiple effects can be 
measured, and the effects do not 
necessarily have to be common 




costs and effects 
since both are 
measured in 
monetary terms. 
Table 1: A comparison of the types of economic evaluations (5)(3) . 
A CEA will be conducted for this study, and methodology will be based on the International 





economic evaluations (6). The reference case consists of eleven principles which are 
transparency, comparators, evidence, study perspective, measure of health outcomes, costs, 
time horizon and discount rate, heterogeneity, uncertainty, constraints and equity 
considerations (6).  
Transparency 
Requires the declaration of all interests by analysts, acknowledgement of limitations to the 
study and the full and accurate description of the decision problem to be reported (6). 
Comparators 
The reference case requires current practice in the context of the decision problem to be used 
as a comparator in the analysis, and where possible the best supportive, noninterventional care 
to be included in the analysis as a comparator (6). 
Evidence 
A transparent, systematic approach in obtaining evidence must be used in carrying out 
economic evaluations (6). The estimates of the clinical effects should be informed through a 
systematic review of the literature (6). 
Study Perspective 
The study perspective must be determined prior to the economic evaluation to ensure that data 
collected is appropriate. The three possible perspectives for an analysis are; providers’ 
perspective, patients’ perspective and the societal perspective. A societal perspective which is 
the broadest perspective should be used in an economic evaluation where possible.  
Measure of Health Outcomes 
The use of a CEA in an economic evaluation allows for the measurement of both morbidity 
and mortality, giving a broader measure of health outcomes (5). QALYs and DALYs are 
commonly used as multi-dimensional outcomes in economic evaluations and are considered 
measures of health (5). QALYs measure an individuals’ life-expectancy adjusted by a health-
related quality of life (HRQoL) factor, with one year of perfect health being valued as one 
QALY (5). DALYs measure the years of life lost added to years lived with a disability (YLD). 
Disease specific outcomes, for example seizure control in epilepsy, can also be used when 
conducting a CEA (5). The IDSI reference case requires a full, transparent description of the 





Measure of Costs 
Costing involves the identification, quantification and valuation of all resources used in the 
implementation of a given health intervention (7). The costs of all interventions included in the 
analysis are measured in monetary terms and are dependent on the study perspective (5). A 
study from a providers’ perspective should measure and value the direct medical costs 
associated with the provision of the intervention. A study from the patients’ perspective should 
include both direct and indirect costs incurred in the provision and use of the intervention. 
Direct costs include both medical and non-medical costs, while indirect costs include loses due 
to reduced productivity (5). Intangible costs such as the value of pain and suffering can also be 
included (5). A societal perspective is inclusive of both the provider and patient costs and 
considers the economic impact of the condition on society. An ingredients approach or a step-
down approach can be used to collect the costs associated with an intervention (5). The 
ingredients approach is a detailed approach to costing which involves the detailed measurement 
of all the resources used in the provision of the intervention (5). The step-down method is a 
more aggregative method of costing which involves estimating the cost of an event using the 
cost of shared resources that are not directly linked to patient use (5). The costing method used 
is dependent on the research question. The IDSI reference case requires the analysis to include 
costs that where not incurred in the study settings for trial-based studies but which will likely 
be incurred if the intervention is to be rolled out (6). The analysis should also include estimates 
of changes in costs due to economies or diseconomies of scale (6). 
Time Horizon and Discount Rate 
Time horizon is the duration over which the health outcomes and costs for the study will be 
calculated (8). In principle, it should be the period over which the costs and/or effects of the 
treatment options under analysis are expected to differ and often a patients’ lifetime is used to 
fully capture these differences (9). The same time horizon must be used for both costs and 
effects (8). Discounting is the adjustment of the value of costs and effects incurred in future 
(over a year after the initiation of the intervention) in order to demonstrate time preference 
(10). The IDSI reference case requires the use of a 3% annual discount rate for both costs and 
effects, with additional analyses exploring different rates, including an annual discount rate 








It refers to the heterogeneity of the population under analysis. Heterogeneity should be 
considered in population subgroups whereby the characteristics of the different populations 
may influence the absolute health effect, or the costs associated with the intervention (6). The 
IDSI reference case requires subgroup analysis to be determined by the evidence base and 
whether the differences between the populations have an important influence on costs and 
effects (6). 
Constraints  
The IDSI reference case requires that financial constraints be explored through a budget impact 
analysis. The budget impact analysis should estimate the implications of implementing the 
intervention using approximations of disease prevalence and numbers in need of the 
intervention (6). The budget impact analysis should also reflect the decision problem and the 
constituency in which the intervention will be used (6). 
Uncertainty 
Uncertainty can be due to the generalization of results from research settings to other settings, 
extrapolation of data, sampling of data or choice of analytic method (11). Sensitivity analysis 
is used in economic evaluations to cater for uncertainty. Three types of sensitivity analyses can 
be used; simple sensitivity analysis, threshold analysis and probabilistic sensitivity analysis. 
For simple sensitivity analysis one or more variables are varied across a plausible range to 
assess the impact of the variables on costs, effects and the resulting Incremental Cost-
Effectiveness Ratios (ICERs) (11). Threshold analysis requires the identification of the values 
of variables at which the decision to implement the intervention might change based on either 
the maximum budget or the ICER threshold (11). For probabilistic sensitivity analysis 
uncertainty intervals are captured around all possible variables using a Monte Carlo simulation 
which involves running the model multiple times using randomly sampled values of the model 
inputs (12).  The IDSI reference case requires the economic evaluation to explore all possible 
sources of uncertainty where feasible (6). 
Equity considerations 
Equity in health care is based on the principle that the availability of health care services should 
be independent of an individuals’ ability to pay (5). There are two dimensions to equity which 





care needs should have equal access to health care, while vertical equity stipulates that 
individuals with different health care needs should be treated differently (5). The IDSI 
reference case requires the use of an appropriate mechanism for the assessment of equity 
implications regarding an intervention based on the decision problem (6). It also requires the 
consideration of equity implications at all stages of the evaluation (6). 
The decision rule for economic evaluations, specifically CEAs is based on the ICER values 
obtained. If the ICER of an intervention is equal to or less than a given threshold that represents 
“willingness-to-pay”, the intervention is considered “cost-effective” and therefore worth 
implementing (5). The ICERs obtained from an analysis can be plotted on a cost-effectiveness 
plane as shown in figure 1. 
 
Figure 1: The cost-effectiveness plane and decision-making. 
 
Economic modelling 
Decision analytical models are used to compare the expected costs and effects of a decision 
option through the synthesis of information from multiple sources and the application of 








Decision trees are the simplest decision analytical model for economic evaluations. The first 
point of a decision tree is the decision node which represents the decision question (13). The 
branches from the decision node represent the available intervention options. The pathways 
that follow each intervention option represent a series of logically ordered alternative events 
(13). Each set of options emanates from a chance node and the alternatives at each chance node 
must be mutually exclusive with their probabilities of occurrence adding up to one (13). The 
end points of each pathway are represented by terminal nodes to which the values for the costs 
and effects are assigned (13). Decision trees lack explicit time variables; therefore cannot be 
appropriately used in economic evaluations with time dependent elements (13). 
Markov models 
In a Markov model patients are assumed to reside in one of a finite number of health states at 
any point in time and can transition between those health states over several cycles (13). The 
probability of remaining in a health state/Markov state or moving to another state is dependent 
on transition probabilities (13). For each cycle the sum of the transition probabilities out of 
each health state must equal 1 (13). The model must have termination conditions, for example 
a specific number of cycles, a proportion of the population passing through or accumulating in 
a health state or the entire population reaching a health state which cannot be exited (absorbing 
state) (13). An assumption is made that the transition probabilities only depend on the current 
health state and are independent of historical experience (13). Each health state will have cost 
and health utility values associated with it. Markov models usually simulate the transition of a 
hypothetical cohort through the model over time, allowing for the estimation of the expected 
costs and effects (13). The estimated costs and effects are calculated through the summing up 
of costs and effects across health states that are weighted by the proportion of the cohort 
expected to be in each state. The values obtained for each cycle are then summed up to 
determine the total costs and effects for the model (13). 
Limitations of economic evaluations 
There is a level of diversity in the methodological requirements for conducting economic 
evaluations in different settings, making it challenging to compare resulting studies for 
decision-making and to transfer study results to other settings (14). Decision makers are 





vulnerability of the studies to bias due to poor availability of quality data, especially in the 
context of LMICs (14). The IDSI reference case for economic evaluations aids with 
harmonizing the methodology of economic evaluations and encourages transparency in the 
conduct of analyses, improving decision-makers confidence in results obtained. Social 
expectations that health related decisions must be made based on the best interests of the patient 
also limit the use of economic evaluations (6)(14). These expectations may lead to conflict 
when deciding on the implementation of an intervention that is not cost-effective or considered 
to be value for money but can save a life (14).  
Due to the use of both QALYs and DALYs as effect measures in CEAs, decision makers are 
required to compare results from different studies using DALYs and QALYs, with no formula 
on how to convert one to the other, or information on how the two are comparable. This limits 
the use of economic evaluations, specifically CEAs in the policy space.  
Selection process for medicines for use in the South African public health sector 
The National Drug Policy (NDP) for South Africa which was published in 1996 resulted in the 
establishment of the Essential Drug Program (EDP) which in turn resulted in the formation of 
a Ministerial appointed National Essential Medicines List Committee (NEMLC) (15). The 
main objective of the NDP was to improve equitable access to medicines through addressing a 
range of components including the selection of medicines (16). One of the economic objectives 
of the NDP is to promote the cost-effective and rational use of medicines and this can be 
achieved through the use of economic evaluations in the medicine selection process (16). The 
committee has a multi-professional membership and is responsible for the development of the 
Standard Treatment Guidelines (STG) and the associated Essential Medicines List (EML) for 
the primary health care (PHC) and secondary hospital levels of the public sector (15). For the 
tertiary/quaternary level the EML is a list of recommendations and non-recommendations of 
treatments for specific conditions which is found on the National Department of Health 
(NDoH) website (15). Essential medicines are defined as medicines that satisfy the priority 
health care needs of the population (17). South Africa’s first STG/EML was published for PHC 
in 1996, and 12 editions of PHC, paediatric and adult hospital level STG/EMLs have been 
published since (15). The process for reviewing chapters of the STG/EML starts with a notice 
for the request for comments which results in the circulation of the chapter to the appropriate 
stakeholders (15). The medicines for consideration are selected through the Evidence Based 
Medicine (EBM) process which looks at the quality, safety, efficacy and cost-effectiveness of 





support structure for NEMLC reviews the medicines under consideration based on reviewer 
guidelines and interpret the results obtained from the EBM process and tables 
recommendations to NEMLC (15). NEMLC then takes the recommendations by the technical 
expert review committee under consideration and makes the decision regarding the proposed 
amendments (15). This is then circulated again to stakeholders for comments. The Minister of 
Health must endorse the decision by NEMLC before the amendment of the STG/EMLs (15). 
The selection process is dynamic and consists of multi-disciplinary and multi-stakeholder 
contributions in decision-making (15). 
The provincial Pharmacy and Therapeutics Committees (PTCs) form part of the support 
structures for NEMLC (15).  The PTCs have a degree of autonomy as their provincial Member 
of the Executive Council (MEC) or Head of Department allows the selection of medicines for 
provincial use that are funded from the provincial budget (16). Decision making regarding the 
selection of medicines therefore may differ by province, resulting in inequitable access to 
medicines (16). 
Background information on epilepsy  
Disease process 
Epilepsy is a chronic neurological condition responsible for considerable morbidity and 
mortality globally (18). Epilepsy is characterized by recurrent unprovoked seizures, which are 
brief episodes of involuntary movements and is associated with excess morbidity and mortality, 
which have been shown to be higher in LMICs compared to high income countries (19)(20). 
Causes of epilepsy-related mortality range from direct causes such as sudden unexpected death 
in epilepsy (SUDEP) and status epilepticus, and indirect causes such as suicides and 
complications of antiepileptic drugs (21). Seizures are classified based on their origin in the 
brain (22). Focal seizures originate in a network localized in one brain hemisphere and may or 
may not lead to the loss of consciousness (22). Focal seizures can spread to the rest of the brain, 
resulting in a generalized seizure (secondary generalization) (18). Generalized seizures rapidly 
engage networks from both sides of the brain and range from brief absence attacks to major 
convulsions (18). Seizures can also have an unknown origin (22). Epilepsy has multiple 
underlying causes including head injuries, vascular insults, hippocampal sclerosis, cortical 
dysgenesis, drug or alcohol abuse and infectious diseases, such as neurocysticercosis and 
HIV/AIDS (23)(18). Diagnosis of epilepsy is usually through a diagnostic clinical interview 





neuroimaging. A diagnostic clinical interview requires a detailed description of the event 
experienced by the patient prior to, during and after the seizure attack. This also involves 
interviewing any witnesses of the seizures. This assists with the classification of the seizure 
type which is essential in determining the appropriate treatment. 
HRQoL 
Quality of Life is defined as “an individuals’ perception of their position in life in the context 
of the culture and value system in which they live and in relation to their goals, expectations, 
standards and concerns” (24). HRQoL represents the gap between the reality of an individuals’ 
perception of their health and their expectation (24). Frequency and severity of seizures, 
presence of psychiatric disorders, polytherapy, side-effects from AEDs and the presence of a 
comorbidity have been found to be strongly related to a reduced HRQoL (24) (25). Epilepsy 
significantly impacts an individuals’ cognitive and psychological wellbeing, resulting in a 
decreased health-related quality of life (HRQoL) (25). The frequency and severity of seizures 
can lead to cognitive dysfunction, which can be reduced or reversed through effective seizure 
control (25). A study conducted found that the HRQoL, especially social function and seizure 
worry improved in newly diagnosed epilepsy patients after successful treatment with AEDs for 
a period of 12 months (25). In this study, the seizure free group demonstrated a 6.7 mean point 
increase on the Quality of Life in Epilepsy-31 test, while the non-seizure free group 
demonstrated a 0.3 mean point decrease (25). The incidence of psychiatric disorders in people 
with epilepsy is also significantly higher than in the general population, with up to 50% to 60% 
of patients with chronic epilepsy having at least one mood disorder such as depression or 
anxiety (26). Patients on monotherapy have been found to have a better quality of life due to 
less medicine-related side effects (27). Clinical counselling, patient education together with 
community support groups can also assist in addressing some of the psychosocial issues that 
negatively impact the quality of life of epileptic patients (28). 
Epilepsy treatment 
Epilepsy has multiple treatment options which include neurostimulation, pharmacotherapy, 
surgery and the ketogenic diet.  
Neurostimulation 
Excitability-reducing neurostimulation is used as alternative therapy for refractory epilepsy 





The ketogenic diet 
The ketogenic diet is a low-carbohydrate, adequate protein and high-fat diet (30). It has been 
established as an effective nonpharmacological treatment option for the management of 
refractory epilepsy (30). Multiple theories have been put forward to explain the efficacy of the 
ketogenic diet, with one of them being that ketone bodies have similar anticonvulsant activity 
to that of antiepileptic drugs (30). The brain is an avid user of glucose as a source of energy, 
but in a carbohydrate restricted diet, the brain no longer uses only glucose for energy, but also 
starts to oxidise ketone bodies obtained from the fat component of the diet (30). Efficacy of the 
ketogenic diet is dependent on multiple factors such as the type of seizures, aetiology of the 
seizures, age of the patient (use is preferred in children between the ages of 2 and 10), 
compliance with diet and length of follow-up (30). Side effects of the ketogenic diet include; 
hypoglycaemia, dehydration, poor appetite, nausea, vomiting and constipation (30).  
Surgery 
Epilepsy surgery is the best treatment for focal refractory epilepsy, especially when it is 
associated with a focal lesion (31). On average, about 10 percent of epileptics could be 
considered good candidates for surgery, but fewer than 4% of potential candidates receive 
surgical treatment due to the invasive and irreversible nature of surgery (31). Although the 
presurgical evaluation required for epilepsy surgery and the actual surgery cost a lot of money, 
studies have shown that the benefits achieved in terms of  clinical improvements and reduced 
requirements for medication and medical services in the long-run outweighed the surgical 
costs, making the intervention cost-effective (31). 
Pharmacotherapy 
Pharmacotherapy with AEDs is the most common treatment for people with epilepsy. 
Treatment is long-term , lasting several years and often a lifetime (32). Seizure type, patients’ 
age, gender and comorbidities are some of the factors that should be considered when deciding 
on the appropriate drug for treatment (32). AEDs can be divided into first- and second-
generation drugs. First generation drugs are AEDs that where licensed prior to the 1990s and 
include phenytoin, valproate and carbamazepine (22). Second-generation AEDs are those 
approved and registered during and after the 1990s, these include lamotrigine and levetiracetam 
(22). Second-generation AEDs have been found to generally have better tolerability, improved 
safety profiles and fewer drug interactions in comparison to first-generation AEDs (22). At 





more AEDs due to lack of efficacy of available drugs or treatment limitations due to side effects 
(22). Monotherapy is advised in the treatment of epilepsy due to drug interactions between 
some of the AEDs in some instances, for example carbamazepine and lamotrigine, 
complicating the use of adjunctive therapy (33). Polytherapy should preferably only be used 









Comparison of anti-epileptic agents 
Table 2: Treatment options for newly diagnosed epilepsy under the South African Standard Treatment Guidelines (34). 
Drug Dose Mechanism of Action Indications Adverse Effects 
Lamotrigine Initially 25mg daily for 2 weeks, then 
50mg daily for 2 weeks, thereafter 
increase by up to 50-100 mg every 1-2 
weeks according to response. Usual 
maintenance dose is 100-200 mg/day 
up to 500mg/day as required. 
Inhibition of the release 





Monotherapy or add-on therapy for focal 
epilepsy with or without secondary generalized 
tonic-clonic seizures and in primary generalized 
tonic-clonic seizures; adjunctive therapy for 
children, and for Lennox-Gastaut syndrome. 
Also registered for bipolar affective disorder. 
Maculopapular rash develops within 4 
weeks of initiating treatment, which 
occasionally progresses to severe 
generalized hypersensitivity reactions 
such as Steven-Johnson syndrome. 
Carbamazepine Initially 100-200 mg twice daily, with 
increments of 100-200 mg/day at 
weekly intervals according to seizure 
control and adverse effects 
Sodium channel 
blockade. 
First-line management of generalized and focal 
seizures but not effective in the treatment of 
absence seizures or atonic seizures. 
Sedation, ataxia, gastrointestinal 
effects. Side effects may subside 
spontaneously after 7-14 days’ 
treatment, or with dose reductions. 
Valproate Initially 600mg/day in divided doses, 
increase by 200mg/day at 3-day 
intervals until control is achieved. 
Maximum 2.5g/day 
Unknown All forms of epilepsy. Also used as prophylaxis 
for migraines and for control of the acute manic 
phase of bipolar disorder. 
Gastrointestinal effects, dose-related 
CNS effects such as fatigue and 
sedation, ataxia and dysarthria. 
Teratogenic in pregnancy, classified as 
a category D drug. 
Phenytoin Initially 150-300 mg daily, after 5-20 
days small increments may be made if 
required. Maintenance range: 5-
7mg/kg/day. 
Unknown All forms of epilepsy except absence and 
myoclonic seizures. Also used in status 
epilepticus. 
Related to plasma levels. Nausea, 
vomiting, tremor, ataxia, nystagmus 
and speech disturbances. Category D 
drug in pregnancy due to increased risk 
of fetal abnormalities. 
Levetiracetam Initially 250 mg twice daily, increasing 
to initial therapeutic dose of 500mg 
twice daily. Adjust according to need 
with 500 mg twice daily every 2-4 
weeks. Maximum dose 3g/day 
Unknown Mono- or add-on therapy for focal seizures in 
patients from 16 years of age. Add-on therapy 
for primary generalized tonic-clonic seizures 
from 16 years of age. Add-on therapy for 
myoclonic seizures in adults and adolescents 
from 12 years of age. 
Somnolence, fatigue, dizziness. 
Infrequent occurrence of serious side 






Phenytoin has a narrow therapeutic range therefore has a high potential for toxicity especially 
in chronic use (35). A change in formulation of phenytoin can also result in toxicity due to the 
complex pharmacokinetics of the drug, necessitating the maintenance of the same brand in 
treatment which is challenging in the public health sector (35). Phenytoin, lamotrigine and 
carbamazepine are associated with Steven-Johnsons syndrome which is potentially life-
threatening (35). This is especially a concern in the context of South Africa due to the high 
prevalence of HIV which increases the risk of getting Steven-Johnson syndrome. Phenytoin 
and carbamazepine increase the metabolism of hormonal contraceptives, potentially rendering 
them ineffective (35). This is especially a problem if pregnancy occurs during long-term use 
of phenytoin as prophylaxis for seizure control as it has teratogenic effects and is associated 
with low folic acid levels (35). The use of sodium valproate during pregnancy is also associated 
with congenital malformations (35). Levetiracetam has a favorable pharmacokinetic profile 








         Clinical effectiveness and/or efficacy of levetiracetam as first-line treatment in newly diagnosed epilepsy 
 















2013 (36)   
 
 
 Patients ≥16 years of 
age with ≥2 
unprovoked seizures 
in the previous 2 
years and ≥1 in the 
previous 6 months 
 Patients were 
excluded if they had 
been treated with 
LEV, VPA or CBZ 
for any indication or 
treated for epilepsy 
with any other AED 
in the last 6 months 





trial with a 
two-parallel-
group design 










 Time to 
first 
seizure. 




LEV and standard 
AEDs. HR (95% 
CI) 0.90 (0.74 to 
1.08). 
 Time to first 
seizure was 
significantly 
longer for patients 
on standard AEDs 
compared to 
patients on LEV. 
HR (95% CI) 1.20 
(1.03 to 1.39). 
 LEV monotherapy 
was not superior to 
standard AEDs for 
the global 
outcome, namely 














 Adults with ≥2 
partial or generalized 
tonic–clonic seizures 
in the previous year 
 Exclusion criteria - 
pseudoseizures, 
seizures occurring 














trial with a per 
protocol 
analysis 















freedom rates in 
newly diagnosed 
epilepsy patients at 
optimal dosing in a 
setting mimicking 
clinical practice 
 Withdrawal rates 
were higher for 
CBZ (19.2%) 
compared to LEV 
(14.4%) 





Comparative costs of AEDs 
The acquisition costs of second-generation AEDs as a group are higher than those of first-
generation AEDs, but their use in clinical practice is justified because they are more effective 
in controlling seizures (38). 
 
Economic impact of epilepsy 
Epilepsy is associated with multiple challenges for the epileptic individual which includes 
medical, psychological, social and economic problems (39). Economic problems are associated 
with both the direct and indirect costs for the treatment of epilepsy. Indirect costs include loss 
of income due to the reduced productivity associated with morbidity (39). Epileptics have a 
limited potential in the labour market, with unemployment and underemployment occurring 
more frequently in epileptics compared to the rest of the population (39). Uncontrolled 
epileptics also require a lot of care and attention, which may require relatives to devote 
productive hours to the care of the epileptic, reducing productivity (39). This in turn affects 
national productivity and, in some instances, returns on investment with regards to the labour 
market. The estimated percentage of the global burden of disease associated with epilepsy in 
developing countries is about 90%, while only 20% of all epilepsy related health expenditure 
is spent in developing countries (39). 
Epilepsy in South Africa 
The burden of epilepsy in South Africa is largely unknown, but is estimated to be about 1% 
(40). Two studies conducted in the South African context in the 1960s reported a prevalence 
of 2.2/1000 and 3.7/1000 (41)(42) . A study conducted on the prevalence of epilepsy in children 
between the ages of 2 and 9 in rural South Africa found a lifetime prevalence of 7.3/1000 and 
an active prevalence of 6.7/1000 (43). For the study, active prevalence was defined as the 
proportion of participants who had experienced an epileptic seizure in the preceding 2 years or 
had recently been on or was currently on AEDs (43). ‘Lifetime’ prevalence was defined as the 
proportion of participants with a history of epilepsy (43). Trauma and infectious diseases such 
as HIV/AIDS and neurocysticercosis are common causes of epilepsy in South Africa (23). 
Epilepsy usually manifests in HIV positive patients in the advanced stages of the disease and 
can be a direct result of an HIV infection of the central nervous system, or a result of an 
opportunistic infection (23). The cultural beliefs and attitudes of both the epileptic and society 





and stigma associated with epilepsy, with widely held beliefs that it is caused by supernatural 
forces and is contagious (23). This belief in the supernatural origins of epilepsy has fuelled the 
important role of traditional healers in the management of epilepsy in  the rural African setting 
(44). Given this belief, there is a high likelihood that epileptics combine Western medicine 
with traditional treatments, which may negatively impact treatment outcomes. This brings rise 
to a need to accompany pharmacological treatment with patient education. In South Africa 
epilepsy is mainly treated through pharmacotherapy. The treatment gap for epilepsy in LMICs 
is estimated to be 75% due to a poor resource base (20). This includes poor infrastructure, 
insufficient availability of cost-effective drugs and scarcity of trained medical staff (44) On 
initiating pharmacotherapy, the aim is to use a single anticonvulsant for seizure control (45). 
The guidelines stipulate that if initial treatment fails, a second medicine must be tried (45). If 
both drugs fail, and alcohol and poor adherence have been excluded, then combination therapy 
may be required (45). In the South African public health sector carbamazepine, lamotrigine 
and phenytoin are the recommended first-line treatments for both partial seizures and 
generalized tonic-clonic seizures (45). Valproate is used as second-line treatment for patients 
who do not stabilize on the above stated medicines or who cannot tolerate them (45). 
Lamotrigine and valproate are the recommended treatments for HIV positive epileptics due to 
the potential drug interactions with antiretroviral drugs of phenytoin and carbamazepine (45). 
Levetiracetam is under consideration for inclusion on the South African Essential Medicines 
List due to its favorable side-effect profile and minimal drug interactions. This is especially 
important considering the high HIV and hypertension prevalence in South Africa. 
Review of economic evaluations for pharmacotherapy in epilepsy 
Literature search 
Population Adult patients with newly diagnosed epilepsy  
Intervention Levetiracetam OR Lamotrigine OR Valproate OR Carbamazepine OR Phenytoin 
OR Anticonvulsants 
Comparator Levetiracetam OR Lamotrigine OR Valproate OR Carbamazepine OR Phenytoin 
OR Anticonvulsants 
Outcome Economic: 
 cost per utility measure (QALY, DALY) 





 cost per treatment success. 
 
 
Study inclusion criteria 
1. Studies published in English considering human participants. 
2. Cost-effectiveness and cost-minimization studies on epilepsy treatment with one or more 
of the drugs of interest as either a comparator or an intervention as monotherapy. 
 
Study exclusion criteria 
1. Studies considering seizures that are not identified as having a partial or generalized 
origin. 
2. Studies solely targeting children and adolescents. 
















Cost-minimization Studies on epilepsy pharmacotherapy 
The following table is a summary of the cost-minimization studies
Author & Title 
 




Perspective Drugs (daily 







Cost collected Study Findings 
Heaney DC et al. (1998) 
An Economic Appraisal of 
Carbamazepine, Lamotrigine, 
Phenytoin and Valproate as 
Initial Treatment in Adults 
with Newly Diagnosed 
Epilepsy  (46). 
-United Kingdom 
-Patients > 12 years 
with newly diagnosed 







-CBZ - 600 
-LTG - 150 
-PHT - 300 
-VPA - 1000 
 
 
1996 Time horizon 
– 2 years 
 
-Hospital and general 
practitioner consultations 
-Side effects cost 
-Emergency Room attendance 
-Laboratory tests 
-Drug withdrawal 
-Direct drug costs 
- The cost of treatment for the two-year period was 
found to be €795-829 for CBZ, €1,525-2,076 for 
LTG, €736-768 for PHT, and €868-884 for VPA.  
-Sensitivity analysis provided similar relative 
estimates.  
-Use of LTG for newly diagnosed epilepsy is 
significantly more expensive compared to the other 
available choices. 
 
Shakespeare A, Simeon G 
(1998) 
Economic analysis of 
epilepsy treatment: a cost 
minimization analysis 
comparing carbamazepine 




-Patients > 12 years 











-CBZ - 600 
-LTG - 150 
1994 Time Horizon 
– 12 months 
Discount 
Rate- N/A 
-Direct drug costs 
-Costs associated with adverse 
effects 
N.B: An assumption was made 
that the cost of routine care will 
be the same for both drugs 
since there was no difference in 
efficacy. 
-Treatment with carbamazepine costs about one-third 
(£179) of the cost of treatment with LTG (£522) even 
after considering costs associated with the 
management of side effects and therapeutic 
switching. 
 
Heaney DC et al. (2000) 
Cost Minimization Analysis 
of Antiepileptic Drugs in 
Newly Diagnosed Epilepsy 
in 12 European Countries  
(48). 
-12 countries in 
Western and Central 
Europe 











-CBZ - 600 
-LTG - 150 
-PHT - 300 
-VPA - 1000 
      -    Time Horizon 
– 12 months 
Discount Rate 
– N/A 





-Direct costs associated with the use of CBZ, PHT 
and VPA were similar in all countries for all three 
drugs. 
-Direct costs associated with the use of LTG were 
two to four times those of using CBZ, PHT and VPA 
in each of the countries. 





The study conducted by Heaney et al. (1998) investigated the use of carbamazepine, 
lamotrigine, valproate and phenytoin in the treatment of newly diagnosed epilepsy (46). The 
study found that the cost of using lamotrigine for treatment was higher than that of the other 
drugs under analysis. The drug costs of lamotrigine and the costs incurred during the titration 
period were driving factors in the overall cost of treatment. This study was very robust with 
extensive sensitivity analysis, with the costing model being applied to all available randomised 
control trial data (46). The findings from the various combinations of assumptions and modes 
of analysis were consistent, confirming validity of the study (46). The findings were supported 
by the cost-minimization study conducted by Heaney et al. (2000) in 12 European countries 
which found that the direct costs associated with the use of lamotrigine were two to four times 
the direct costs of using carbamazepine, phenytoin and valproate in each of the countries (48). 
A cost-minimization study by Shakespeare et al. (1998) in the United Kingdom found that 
treatment with carbamazepine for newly diagnosed epilepsy cost about one-third (£179) of the 
cost of treatment with lamotrigine (£522) even after considering costs associated with the 
management of side effects, supporting the findings by Heaney et al. (2000) in the 12 European 
countries (47). All the studies identified support the assertation that second-generation AEDs 
have a higher associated cost of treatment compared to first-generation AEDs. 
The treatment model for the study by Shakespeare et al. (1998) also considered second-line 
treatment in case of treatment failure in the first year of treatment. This inclusion was accounted 
for in the sensitivity analysis. The study focused on costs incurred in the treatment of side 
effects and not those incurred in routine care, as an assumption was made that the resources 
used would be the same due to an assumed equal efficacy. This assumption may have affected 
the accuracy of the model as routine care for the initiation of carbamazepine therapy is different 
from that of initiating lamotrigine therapy since the initiation of lamotrigine requires a titration 
period.  
All the studies clearly identified the study setting, treatments under analysis, costs identified, 
time horizon and were applicable the study perspective was clearly stated. The studies assumed 
equal efficacy of the AEDs under analysis. All the studies where model-based with the 
structures of the treatment pathways devised from expert opinion based on clinical practice. 
The results obtained from the included cost-minimization studies show that first-generation 
AEDs in epilepsy treatment are less costly compared to second-generation AEDs. Within the 
first-generation AEDs the treatment costs incurred from the providers’ perspective appear to 





Western and Central Europe, considerably affecting transferability of the results to the setting 





Cost-effectiveness analysis for the monotherapy of epilepsy 
The studies identified below are cost-effectiveness analysis containing AEDs used as monotherapy in the treatment of epilepsy. 
Author Study Setting and 
population 












ICER Calculation ICER values where applicable and main 
study findings. 
 
Chisholm (2005)  
Cost-effectiveness of 
first-line antiepileptic 
drug treatments in the 
















Model-Based using a 
state-transition 
population model 
with three possible 




-10 years  





DALYs lost ICERs for all treatment 
options were calculated 
relative to a “Do Nothing 
Approach”. 
-ICER range for PHT and PB: I$ 800 – I$ 
2,000 per DALY averted. 
-Average ICER range for CBZ and VPA:  
I$ 1,100–3,000 per DALY averted. 
-PHT and PB were found to be the most 
cost-effective options. 
Knoester et al. (2007)  
A cost-effectiveness 
decision model for 
antiepileptic drug 








- Studies included 
had a study 
population of 









-CBZ followed by 
LTG as second line 
treatment 
-CBZ followed by 
VPA as second line 
treatment 
-LTG followed by 
CBZ as second line 
treatment 
-LTG followed by 
VPA as second line 
treatment 
-VPA followed by 
CBZ as second line 
treatment 
-VPA followed by 
LTG as second line 
treatment 
Model-based using a 




success and failure. 
-1 year 
-N/A 
Euros (€) -Complete success 
(defined as a patient 
being seizure free) 
-Partial Success 
(defined as a 
reduction in seizure 
rate by at least 50%) 
-Failure (defined as 
inadequate seizure 




ICERs were calculated 
relative to the previous 
less costly option. CBZ 
followed by valproate as 
second line treatment 
was used as the reference 
treatment since it was the 
least costly. 
-The ICER of CBZ followed by LTG 
relative to the CBZ followed by VPA 
strategy was €6,079 per additional 
complete success patient. 
-The ICER of LTG followed by VPA 
relative to CBZ followed by VPA was 
€40,422 per additional complete success 
patient. 
-CBZ followed by VPA as second line 
treatment was found to be the most cost-
effective strategy. 
-Use of LTG as second-line treatment was 
found to likely be the most cost-effective 
option in a case were willingness to pay 
was more than €6,000 for an additional 
complete success patient. 
-The rest of the strategies where dominated. 
 
 
Ranjana et al. (2017) 
Cost-effectiveness 
analysis (CEA) of 
Antiepileptic Drug 










analysis using a 
decision-tree model 





-Complete success  
-Failure of seizure 
control 
ICER was calculated 
relative to the previous 
less costly option. CBZ 
followed by the addition 
-The ICER for TPM with CLB as add on 
therapy was US$ 764.98 per additional 









From a Tertiary Care 
Hospital in India (38). 





For each of the first-
line treatment options 
CLB was used as add 
on therapy in the case 
of treatment failure 
in the first six months 
of treatment. 
complete success 
and failure of 
treatment.  
of clobazam was used as 
the reference treatment 
since it was the least 
costly. 
-The LEV with CLB as add on therapy was 
the costliest treatment strategy.  
-The strategies containing PHT, VPA and 
OXC as first-line treatment were 
dominated. 
-TPM with clobazam as add on therapy was 
found to be a cost-effective strategy.  
-The study concluded that the use of TPM 
alone, followed by CLB as add on therapy 
was more cost-effective compared to CBZ 
alone followed by CLB as add-on therapy, 
-The WHO threshold was used to 
determine cost-effectiveness. 
Marson et al (2007)  
Longer-term outcomes 




-Patients ≥5 years 
in the United 















Trial-based study -2 years 
-3.5% for 
costs 
Pounds (£) -QALYs gained 
-seizures avoided 
ICER was calculated 
relative to the previous 
less costly option and not 
based on a baseline. 
CBZ was considered as 
the standard treatment. 
-Economic analysis supported the use of 
LTG over CBZ in terms of both cost per 
seizure avoided and cost per QALY gained. 
-Results did not support the use of GBP or 
TPM over the standard treatment of CBZ. 
-Uncertainty with regards to the 
comparison of CBZ and OXC. 
Marson et al. (2007)  
Longer-term outcomes 




-Patients ≥5 years 
in the United 









Trial-based study -2 years 
-3.5% for 
costs 
Pounds (£) QALYs gained 
-seizures avoided 
ICER was calculated 
relative to the previous 
less costly option and not 
based on a baseline. 
VPA was considered as 
the standard treatment. 
 
-Economic analysis based on cost per 
seizure avoided supported that VPA should 
remain the first-choice drug for idiopathic 
generalized or unclassified epilepsy.      
-The cost per QALY analysis suggests that 
there is a high probability that TPM is a 
cost-effective alternative to VPA 
Beghi et al. (2008) 
Economic analysis of 
newer antiepileptic 
drugs (52). 













N.B for generalized 
seizures valproate 
was only compared to 
lamotrigine. 
Model-based study 
with a probabilistic 
model 
-15 years Pounds (£) QALYs gained ICER was calculated 
relative to the previous 
less costly option and not 
based on a baseline. 
 
-For partial seizures valproate was found to 
be the most cost-effective treatment option 
with an ICER of £ 11,731 
-LTG was dominated by VPA for the 
treatment of generalized seizures. 









with a probabilistic 
model 
-15 years Pounds (£) QALYs gained ICER was calculated 
relative to the previous 
-Both VPA and LTG were dominated in the 







refractory epilepsy  
less costly option and not 
based on a baseline. 
 
Remak et al. (2003) 
A Markov model of 
treatment of newly 
diagnosed epilepsy in 















N.B: All possible 
combinations of the 3 
drugs as first- and 
second-line treatment 
were included in the 
analysis. 
Model-based study 
using a Markov 
model with four 
Markov states; 
seizure free, not 
seizure free, switch 
to new treatment and 
dead. 
-15 years Pounds (£) QALYs gained ICER values were 
calculated for each 
strategy relative to all the 
other strategies under 
analysis. 
-The combinations of TPM and CBZ as 
first- and second-line treatment were both 
considered as the most cost-effective 
treatment options. Both scenarios had 













N.B: All possible 
combinations of the 3 
drugs as first- and 
second-line treatment 
were included in the 
analysis. 
Model-based study 
using a Markov 
model with four 
Markov states; 
seizure free, not 
seizure free, switch 
to new treatment and 
dead. 
-15 years 
-6% for costs 
-1.5% for 
effects 
Pounds (£) QALYs gained ICER values were 
calculated for each 
strategy relative to all the 
other strategies under 
analysis. 
-Topiramate followed by lamotrigine as 
second-line treatment was found to be the 
most cost-effective treatment option for the 
treatment of generalized epilepsy. 
 
 
Hawkins et al. (2005) 
Assessing the Cost-
Effectiveness of New 
Pharmaceuticals in 
Epilepsy in Adults: 
The Results of a 
Probabilistic Decision 
Model (54). 














using a state 
transition model 















in all treatment 
failure. Death can 
-15 years 
-6% for costs 
-1.5% for 
effects 
Pounds (£) QALYs gained -ICER was calculated 
relative to the previous 
less costly option and not 
based on a baseline. 
-QALY values obtained for the various 
treatment options were very similar with a 
difference of 0.038 units, demonstrating 
equal efficacy among the drugs. 
-The LTG and OXC strategies were found 
to be dominated by the CBZ, VPA and 
TPM strategies. 
-VPA was found to be the most cost-
effective treatment option with an ICER of 







occur at any stage in 
the model. 












using a state 
transition model 















in all treatment 
failure. Death can 
occur at any stage in 
the model. 
-15 years 
-6% for costs 
-1.5% for 
effects 
Pounds (£) QALYs gained -ICER was calculated 
relative to the previous 
less costly option and not 
based on a baseline. 
-VPA dominates LTG. 
Wilby et al. (2003) 
A rapid and systematic 
review of the clinical 
effectiveness, 
tolerability and cost 
effectiveness of newer 
drugs for epilepsy in 
adults (33). 














Model-based study -1 year 
-N/A 
Pounds (£) QALYs gained -ICER was calculated 
relative to the previous 
less costly option and not 
based on a baseline. 
-CBZ, LTG and OXC were dominated. 
-VPA was the most cost-effective treatment 
option. 
-TPM is cost-effective at a high ICER 
threshold of more than £60,000. 
-Patients in the 
United Kingdom 
with refractory 









Model-based study -1 year 
-N/A 
Pounds (£) QALYs gained -ICER was calculated 
relative to the previous 
less costly option and not 
based on a baseline. 
-CBZ was the most cost-effective option, 
with the rest of the treatment strategies 
dominated. 





The study by Chisholm (2005) conducted for the WHO in its developing subregions and the 
study conducted by Ranjana et al. (2017) in India were the only CEAs conducted analysing the 
use of monotherapy in the treatment of epilepsy in developing countries found during this 
review. The study by Chisholm (2005) compared the cost-effectiveness of first-generation 
AEDs in the treatment of idiopathic epilepsy and other epilepsy syndromes (49). It compared 
the use of phenobarbitone, phenytoin, carbamazepine and valproate (49). The analysis 
considered both treatment response and patient adherence at different population-level 
intervention coverages in an attempt to better capture treatment effectiveness (49). Phenytoin 
and phenobarbitone were found to be the most cost-effective treatment options and the scaling 
up of treatment coverage from 50% to 80% was found to be favourable in the African context 
(49). A drawback of the study was that all types of epilepsy were treated as one syndrome, 
therefore there was no consideration for the drug of choice for each seizure type. The study 
also did not include the costs associated with the treatment of side-effects associated with each 
treatment option, which may have inevitably affected the analysis as the impact of side-effects 
on quality of life was considered through the use of disability weights. 
The study by Ranjana et al (2017) looked at patients with newly diagnosed epilepsy and 
compared the use of phenytoin, valproate, carbamazepine, levetiracetam, oxcarbazepine and 
topiramate as first-line agents followed by the addition of clobazam as an adjunctive in case of 
treatment failure in the first six months of treatment (38). The results showed that levetiracetam 
as first-line treatment was the costliest treatment option and topiramate, a second-generation 
AED, as first-line treatment was the most cost-effective treatment option (38). The cost-
effectiveness of topiramate as first-line treatment for newly diagnosed epilepsy was also 
supported by studies by Remak et al. (2003) and Marson et al (2007) (51)(53). The study by 
Wilby et al. (2003) concluded that the use of topiramate may be cost-effective in a context with 
a high willingness to pay threshold (33). Studies by Ranjana et al (2017) and Knoester et al 
(2007) were conducted from a societal perspective providing a more holistic picture of the 
economic burden exerted by epilepsy and the impact of each treatment option on society. These 
studies also used disease specific outcomes reducing the level of uncertainty by avoiding the 
conversion of disease specific outcomes to universal outcomes. Although this can be an 
advantage for the analysis, it limits the comparability of the obtained results to the other studies 
identified in this analysis and in the health system.  
Prior to running an integrated cost-effectiveness model, Wilby et al. (2003) conducted a 





identified four studies with similar findings that even when the most optimistic treatment 
scenario for the newer AEDs was compared to the worst-case scenario for the older drugs, 
monotherapy with the older drugs was considerably less costly, and therefore concluded that 
second-generation AEDs should not be used as first-line therapy for newly diagnosed epilepsy 
patients (33). None of these studies identified included levetiracetam as a comparator. Beghi 
et al (2008) also conducted a systematic review before conducting an integrated analysis which 
reached the same conclusions as those reached by the systematic review by Wilby et al. (2003). 
The only exception was the finding by Beghi et al (2008) that the use of topiramate over a 
fifteen-year time horizon dominated all first- and second-generation AEDs under analysis. 
Overall the studies that contained both first- and second-generation AEDs in the analysis did 
not provide conclusive evidence as to whether first-generation AEDs as a therapeutic class are 
more cost-effective compared to second-generation AEDs. Topiramate was found to be cost-
effective in scenarios where there was a high willingness to pay threshold. The findings from 
the SANAD study by Marson et al. (Arm A) (2007) supported the use of lamotrigine as first-
line treatment over the use of carbamazepine (51). The study conducted in the United Kingdom 
by Wilby et al  (2003) found valproate to be the most cost-effective monotherapy for epilepsy 
and carbamazepine to be the most cost-effective option for refractory epilepsy (33). The study 
by Hawkins et al. (2005) also included an analysis of the use of the drugs under analysis as 
adjunctive therapy in refractory epilepsy for partial seizures and found oxcarbazepine to 
dominate the other treatment options (54).  
The comparison of the various studies identified in this review was challenging due to the 
differences in study design, study populations and the cost items included in the various 
analyses. 
Overall the results from the identified studies do not answer the question currently posed in the 
South African public health sector of whether levetiracetam is more cost-effective than the 
current available treatment options. Transferability of the results obtained in the various 
contexts of these studies to the South Africa context is difficult due to the absence of a 
willingness to pay threshold in the South African public health sector. There is need for the 
development of a willingness to pay threshold through the continued use of cost-effectiveness 
analysis in health-related decision making. 
In future studies researchers should consider specifically recruiting patients based on their 





also consider the inclusion of sub-group analysis for the cost-effectiveness of AEDs in 
populations such as pregnant women, lactating women, the elderly and HIV-positive patients 
especially in the context of South Africa. There is need for prospective trial-based studies to 
capture accurate information on both the costs and effects associated with the various treatment 
options. The continued use of conflicting literature from past studies in the development of 
epilepsy related cost-effectiveness models results in the continued recycling of the high levels 
of uncertainty associated with the studies. 
Recommendations by HTA agencies 
NICE (National Institute for Health and Clinical Excellence) 
The recommended first-line treatment in patients with newly diagnosed epilepsy with focal 
seizures is either carbamazepine or lamotrigine (55). Levetiracetam was not cost-effective at 
the June 2011 unit costs which were used to inform the treatment guidelines (55). The 
recommended first-line treatment in patients with newly diagnosed epilepsy with generalized 
tonic-clonic seizures is valproate, with lamotrigine as an option for patients who cannot be 
given valproate (55). Levetiracetam is only offered as adjunctive therapy to patients with 
generalized tonic-clonic seizures (55). 
 
CADTH (Canadian Agency for Drugs and Technologies in Health) 
The Canadian guidelines for the treatment of newly diagnosed epilepsy, published in 2011, 
state that pharmacological monotherapy should be initiated but do not specify the appropriate 
agencies to use for each diagnosis (56). The agency conducted a study on the safety and cost-
effectiveness of levetiracetam in the treatment of epileptic patients which was non-conclusive 
with regards to the cost-effectiveness of levetiracetam (56).  
 
SIGN (Scottish Intercollegiate Guidelines Network) 
For the treatment of focal epilepsy in the Scottish public health sector, lamotrigine is 
recommended and is the preferred drug relative to carbamazepine (57). The guidelines 
published in 2018 acknowledge the presence of clinical trial evidence that levetiracetam can 
also be used as monotherapy for the treatment of focal epilepsy (57). In the treatment of genetic 
generalized epilepsy lamotrigine and sodium valproate are recommended (57). Levetiracetam 
is recommended as first-line treatment in some instances, for example in women of 






No cost-effectiveness studies on the first-line treatment of epilepsy have been conducted in the 
South African context or in a similar context using the combination of drugs under analysis. 
Current first-line epilepsy treatment in South Africa is lamotrigine, phenytoin or 
carbamazepine (45). There is need to determine the cost-effectiveness of all the available 
options for AEDs in South Africa due to the vast healthcare needs related to the quadruple 
burden of disease, scarcity of resources and the demand for efficient use of finances. 
Interventions implemented into the healthcare sector must be effective, both clinically and 
economically to ensure access, availability and acceptability of the interventions to patients 
(38). Some countries are estimated to spend as much as 1% of their total national health care 
expenditure on epilepsy care and treatment (19). This demonstrates the high healthcare 
expenditure associated with epilepsy treatment, solidifying the need for evidence-based 
decision making to maximize the efficient use of resources. Some AEDs such as lamotrigine 
may cause hypersensitivity reactions in susceptible patients which can be serious for example 
in the case of Steven-Johnson Syndrome (58). An estimated incidence of hypersensitive 
reactions from AEDs ranges from 1 per 1000 to 1 per 10 000 users (58). Reports have shown 
carbamazepine, phenytoin, phenobarbitone, and lamotrigine to be connected to 
hypersensitivity reactions (58). Phenytoin has a narrow therapeutic range therefore a high 
potential for toxicity especially in chronic use (35). A change in formulation of phenytoin can 
result in toxicity due to its complex pharmacokinetics, leading to the need to maintain the use 
of the same brand which is challenging in the public health sector (35). Phenytoin and 
carbamazepine increase the metabolism of hormonal contraceptives, potentially rendering 
them ineffective (35). This is especially a problem if pregnancy occurs during the use of 
phenytoin as it has teratogenic effects and is associated with low folic acid levels (35). Use of 
sodium valproate during pregnancy is also associated with congenital malformations (35). 
Levetiracetam has a favorable pharmacokinetic profile and has no serious side-effects. 
Although there is not enough evidence of a greater effectiveness of levetiracetam in the 
treatment of newly diagnosed epilepsy, the limited presence of serious side effects, its ease of 
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Introduction: Epilepsy, a chronic neurological disorder has an estimated prevalence of 1% in 
the South African population and an estimated incidence of 0,2%. Epilepsy has multiple 
underlying causes including head injuries, vascular insults, hippocampal sclerosis, cortical 
dysgenesis, drug or alcohol abuse and infectious diseases, such as neurocysticercosis and 
HIV/AIDS. Causes in South Africa are likely to be infectious due to the high HIV and 
tuberculosis prevalence. The condition has substantial individual and societal economic 
impacts, with economic costs ranging from the direct and indirect costs of treatment and loss 
of productivity due to illness. Primary treatment of epilepsy in the South African public sector 
is through pharmacotherapy, with treatment using a single anti-epileptic agent being preferred 
to polytherapy. No cost-effectiveness studies on the first-line treatment of epilepsy have been 
conducted in the South African context or in similar contexts using the combination of drugs 
in this analysis which are levetiracetam, lamotrigine, carbamazepine, phenytoin and valproate. 
The current first-line epilepsy treatment in South Africa is lamotrigine, phenytoin or 
carbamazepine. Levetiracetam is under consideration for use as a first-line treatment due to the 
reported absence of serious side effects, its ease of use, linear pharmacokinetics and reduced 
interactions with other drugs. 
Methods: The study was model-based and conducted from the providers’ perspective, 
specifically in the South African public health sector. It compared levetiracetam, lamotrigine, 
carbamazepine, phenytoin and valproate as first-line treatment in focal seizures (International 
Classification of Diseases (ICD)-10 code: G40.2) and generalized tonic-clonic seizures (ICD-
10 code: G40.3). The population considered for the analysis was adult patients with newly 
diagnosed epilepsy expected to utilize services in the public health sector. The analysis 
consisted of a cost-effectiveness analysis and a budget impact analysis. The budget impact 
analysis was conducted for the first year of treatment for each of the treatment strategies, while 
the cost-effectiveness analysis was conducted for a five-year period. Both a decision-tree 
representing the first six months of treatment and a Markov model representing the rest of the 
treatment period were used for the cost-effectiveness analysis. The methodology for the cost-
effectiveness analysis was based on the International Decision Support Initiative (IDSI) 
reference case. Costs were expressed as South African Rands, 2018 value and effects were 
expressed as Quality Adjusted Life Years (QALYs). Results were expressed as Incremental 






Results: The use of levetiracetam along with the use of phenytoin, valproate and 
carbamazepine in the treatment of newly diagnosed epilepsy was found to be dominated by 
treatment using lamotrigine. Treatment with lamotrigine over a five-year period was found to 
be the least costly option and had the highest number of QALYs gained. The estimated cost of 
treating one case of epilepsy was R1 252 higher using levetiracetam compared to using 
lamotrigine. Levetiracetam had 0,02 QALYs lower than those of lamotrigine. Phenytoin, 
carbamazepine and valproate were found to have the same effect size of 3,97 QALYs. 
Sensitivity analyses were conducted using some levetiracetam-related costs and quality of life 
values. Both the levetiracetam-related costs used in the sensitivity analysis showed that lower 
cost values were associated with less negative ICER values (i.e. levetiracetam became 
comparatively more cost-effective as the levetiracetam-related costs became lower). There 
were no trends observed regarding the impact of the quality of life measures and the controlled 
on levetiracetam treatment variable on the ICER values obtained. 
The pharmaceutical costs of treating newly diagnosed epilepsy with levetiracetam were found 
to be higher in comparison to those of comparators. For a 100% treatment coverage, the cost 
of treatment with lamotrigine, the other second-generation anti-epileptic drug (AED) under 
analysis was about R19 million cheaper compared to treatment with levetiracetam over a one-
year period. Treatment with carbamazepine was found to be the cheapest option, costing about 
R20 million less than treatment with levetiracetam. On inclusion of other health systems costs 
associated with seizure and side-effect treatment levetiracetam was still found to be the costliest 
treatment option while lamotrigine became the least costly option.  
Discussion: The effect sizes of all the treatments under analysis were similar, with a difference 
of 0,04 QALYs being observed between the most effective and the least effective treatment 
option. This led to costs being the main driver of the resulting ICER values. Although 
levetiracetam had the second lowest value for the non-pharmaceutical costs associated with the 
treatment of epilepsy, the high pharmaceutical costs of the drug led to its dominance by 
lamotrigine. Approximately a 93% price reduction is required for levetiracetam to be more 
cost-effective than lamotrigine. The model results for the cost-effectiveness analysis agree with 
the findings from the study conducted to inform the National Institute for Health and Clinical 
Excellence (NICE) treatment guidelines in the United Kingdom, which found that 
levetiracetam was not cost-effective. Lamotrigine is recommended for the treatment of both 





in the United Kingdom and Scotland. It is the only drug recommended for the treatment of both 
indications, with carbamazepine being recommended for the treatment of partial seizures and 
valproate for the treatment of generalized tonic-clonic seizures. 
Conclusion: Levetiracetam was found to not be a cost-effective treatment option for both 
generalized tonic-clonic seizures and partial seizures in the South African public health sector 
context, even when accounting for the titration period and the drug prevalence of Steven 
Johnson Syndrome associated with some of the comparators. 
 
Key Words: epilepsy; health technology assessment; budget impact analysis; cost-
effectiveness analysis; antiepileptic drugs; levetiracetam; quality adjusted life years; newly 






Epilepsy is estimated to have a global prevalence of between 0,4% and 1,0% (1). The 
prevalence of epilepsy in South Africa is largely unknown, but is estimated to be about 1% (2). 
The condition comprises of different seizure types and syndromes, leading to complexities in 
determining incidence, prevalence and prognosis of the disease (3)(4). Seizures are classified 
based on their origin in the brain (5). Focal seizures originate in a network localized in one 
brain hemisphere and may or may not lead to the loss of consciousness (5). Focal seizures can 
spread to the rest of the brain, resulting in a generalized seizure (secondary generalization) (3). 
Generalized seizures rapidly engage networks from both sides of the brain and range from brief 
absence attacks to major convulsions (3). Seizures can also have an unknown origin (5). This 
neurological disorder is associated with an increased mortality rate in uncontrolled patients 
when compared to the general population, with a crude mortality ratio of 3.1 (6). Increased 
mortality in epileptics can be attributed to direct causes such as sudden unexpected death in 
epilepsy (SUDEP) and status epilepticus, and indirect causes such as suicides and 
complications due to antiepileptic drugs (AEDs) (4). Epilepsy has multiple underlying causes 
including head injuries, vascular insults, hippocampal sclerosis, cortical dysgenesis, drug or 
alcohol abuse and infectious diseases such as neurocysticercosis and HIV/AIDS (7)(3). Causes 
in South Africa are likely to be infectious due to the high HIV and tuberculosis prevalence (7). 
Epilepsy also negatively impacts the patients’ quality of life. This is due to the diseases’ 
significant impact on an individuals’ cognitive and psychological wellbeing (8). Frequency and 
severity of seizures, presence of psychiatric disorders, polytherapy, side-effects from AEDs 
and the presence of a comorbidity have been found to contribute to a reduced quality of life 
(9)(8). A study conducted in Korea published in 2015 found that health-related quality of life 
(HRQoL), especially regarding social function and seizure worry improved in newly diagnosed 
epilepsy patients after successful treatment with AEDs for a period of 12 months (8). The 
incidence of psychiatric disorders in people with epilepsy is also significantly higher than in 
the general population, with between 50% and 60% of patients with chronic epilepsy having at 
least one mood disorder such as depression or anxiety (10). Epilepsy also has social 
implications for individuals living with the condition. This is especially true in the African 
context were there are high levels of stigma associated with the disease due to the belief that 
the disease is contagious and a result of a curse (11).  
Epilepsy has multiple treatments including pharmacotherapy, surgery, neurostimulation and 





especially when it is associated with a focal lesion (12). When surgery and pharmacotherapy 
have failed or are not indicated, excitability-reducing neurostimulation is used as alternative 
therapy for refractory epilepsy (13). The ketogenic diet has been established as an effective 
non-pharmacological treatment option for the management of refractory epilepsy, especially in 
children between the ages of two and ten (14). Treatment of epilepsy is primarily through 
pharmacotherapy with AEDs which can be classified as first- and second-generation drugs. 
First generation drugs are AEDs that where licensed prior to the 1990s and include phenytoin, 
valproate and carbamazepine (5). Second-generation AEDs are those approved and registered 
during and after the 1990s and these include lamotrigine and levetiracetam (5). Second-
generation AEDs have been found to have improved safety profiles, better tolerability and 
fewer drug interactions compared to first-generation AEDs (5). Acquisition costs of second-
generation AEDs as a therapeutic class are higher than those of first generation AEDs, but their 
use in practice is justified because they are more effective in seizure control (15). Monotherapy 
is advised for the treatment of epilepsy to minimize drug interactions and because monotherapy 
has been found to be associated with a better quality of life compared to polytherapy due to 
less side effects (16)(17). The current first-line epilepsy treatment in South Africa is 
lamotrigine, phenytoin or carbamazepine (18). Polytherapy should preferably only be used 
when monotherapy with several alternative drugs has been found to be ineffective (16).  
At least 25% of epilepsy patients continue to have seizures despite optimal treatment with one 
or more AEDs due to lack of efficacy of available drugs or treatment limitations due to side 
effects (5). Some AEDs such as phenytoin, carbamazepine, lamotrigine and levetiracetam may 
cause hypersensitivity reactions in patients who are susceptible, for example those with a 
weakened immune system due to HIV (19). Hypersensitive reactions include Steven Johnson 
Syndrome, a rare but serious disorder of the skin associated with painful red blisters and can 
lead to death (20). Phenytoin has a narrow therapeutic range, resulting in an increased 
likelihood of toxicity in chronic use (21). Phenytoin and carbamazepine increase the 
metabolism of hormonal contraceptives, potentially rendering them ineffective (21). This is 
especially a problem if pregnancy occurs during the use of phenytoin as it has a teratogenic 
effect and is associated with low folic acid levels (21). Use of valproate during pregnancy is 
also associated with congenital malformations (21). Lamotrigine, together with carbamazepine 
and valproate are titrated to optimal dose on treatment initiation, in order to minimize adverse 
events and improve tolerability, leading to an increase in the associated treatment costs due to 





due to an increased patient load with regards to hospital visits (22). The titration process is also 
associated with higher health care resource use given the increased number of hospital visits, 
which is not ideal in the resource constrained setting of the South African public health sector 
(22). Suboptimal AED dosing during the titration period may also result in breakthrough 
seizures, further exacerbating costs. 
Epilepsy also presents an economic problem both at a micro- and macro- level, with some 
countries being estimated to spend as much as 1% of their total national healthcare expenditure 
on epilepsy treatment (11). At a personal level epileptics have limited potential in the labour 
market, with unemployment and underemployment occurring more frequently in epileptics 
compared to the rest of the population (23). Uncontrolled epileptics also require a lot of care 
and attention, which may require relatives to devote productive hours to the care of the 
epileptic, reducing productivity (23). The estimated percentage of the global burden of disease 
associated with epilepsy-related morbidity and mortality found in developing countries is about 
90%, while only 20% of all epilepsy related health expenditure is spent in developing countries 
(23). This, together with other factors such as poor infrastructure and scarcity of trained 
medical staff, has resulted in an estimated treatment gap for epilepsy in low- and middle-
income countries (LMICs) of 75% (24). To ensure the efficient use of limited resources for 
epilepsy, especially in developing countries, there is need for economic evaluations to ensure 
that cost-effective treatments are funded. An economic evaluation is defined as the comparative 
analysis of alternative courses of action in terms of costs and consequences (25). In the health 
sector, economic evaluations are utilized for the following purposes; to maximise benefits 
obtained from health care spending, to overcome regional variations in access, to develop 
clinical practice guidelines, to contain costs and manage demand and to provide bargaining 
power with suppliers of health care products (26). Most economic evaluations conducted on 
the treatment of epilepsy were conducted in European settings, limiting their applicability in 
the South African context, due to differences in socio-economic conditions and availability of 
health care resources. A study conducted within the World Health Organization (WHO) 
developing subregions comparing first generation AEDs found that phenytoin together with 
phenobarbitone were the most cost-effective treatment options compared to carbamazepine and 
valproate (27). Another study was conducted in India, evaluating the cost-effectiveness of first- 
and second-line treatment strategies for newly diagnosed epilepsy. The study found the use of 
carbamazepine followed by valproate as second-line treatment to be the most cost-effective 





This study was conducted to determine whether levetiracetam is cost-effective compared to 
carbamazepine, lamotrigine, phenytoin and valproate as first-line treatment for newly 
diagnosed epilepsy in the South African public sector. The study focused on the treatment of 
focal seizures (ICD-10 code: G40.2) and generalized tonic-clonic seizures (ICD-10 code: 
G40.3) (18). No cost-effectiveness studies on the first-line treatment of epilepsy have been 
conducted in South Africa or any other LMIC context using the combination of drugs under 
analysis. 
METHODS 
The study population was epileptic adult South Africans expected to be serviced by the public 
health sector. The study protocol was reviewed by the Human Research Ethics Committee at 
the University of Cape Town (HREC REF: 362/2019). A cost-effectiveness analysis (CEA) 
was conducted to evaluate first-line treatment strategies in patients with newly diagnosed 
epilepsy over a five-year period and a budget impact analysis was conducted for each possible 
treatment strategy for the first year of treatment. The cost-effectiveness analysis was conducted 
in the form of a decision-tree for the first six months of treatment and this was extended through 
a Markov model to a five-year period. Methodology for the cost-effectiveness analysis was 
based on the International Decision Support Initiative (IDSI) reference case (29), while the 
budget impact analysis followed the Principles of Good Practice for ISPOR (International 
Society for Pharmacoeconomics and Outcomes Research) (30). Microsoft excel was used for 
modelling for both the CEA and the BIA. A providers’ perspective, specifically in the public 
sector was adopted for the economic evaluation.  
Data collection  
Secondary data was used for the analysis. Data was collected from literature to inform the input 
parameters for the models, which were in the form of costs and effects.  
Effectiveness parameters were primarily extracted from the Adult Expert Review Committee 
(ERC) levetiracetam medicine review 2019 (Adult ERC Lev MR) (31), any remaining 
parameters were obtained from literature through an iterative snowball search. Both trial-based 
and model-based studies published in English were used to inform effectiveness measures. 
Effects were presented as QALYs, which measure an individuals’ life-expectancy adjusted by 






Pharmaceutical costs were primarily collected from the Master Procurement Catalogue 2018 
of the South African Department of Health. Costs of patient services were mainly obtained 
from the Health Systems Trust Report, District Health Barometer (2017/2018)(33). Costs that 
could not be obtained from the above stated sources were collected from international literature 
and adapted to the South African context and expressed as South African Rands (ZAR), 2018 
values. This was done by applying the average currency conversion rates in the year of study 
to the derived costs, followed by the inflation/deflation of the values obtained to 2018 values. 
Utilization rates were adopted from the Wilby et al (2005) study conducted in the United 
Kingdom and were based on the seizure freedom status of the patient (3). Only the direct 
medical costs associated with the provision of care related to epilepsy were used in the analysis 
based on the study perspective. 
Decision tree model 
An analysis of the decision-tree was conducted for the first six months of treatment based on 
the costs and effects collected for that period. Possible treatment outcomes for each drug were 
expressed as “controlled on treatment”, “controlled off treatment” and “uncontrolled”. Each 
treatment outcome had an associated HRQoL measure and cost value based on the probability 
of occurrence of the outcome. The effect measure for each treatment outcome was calculated 
as the product of the probability of occurrence and the value of the associated HRQoL measure. 
Costs for each outcome were also obtained by multiplying the probability of occurrence and 
the estimated cost of treatment. A controlled patient was defined as seizure free from treatment 
onset for the duration of the cycle and an uncontrolled patient was defined as one who has not 
achieved seizure freedom. The values obtained for both the cost and effect measures for each 
treatment strategy and possible treatment outcome were transferred to the Markov model. 
 






A Markov Model was used to calculate costs and effects over a five-year period. Each Markov 
state was associated with a health outcome and a cost value. Five iterations of the model were 
evaluated based on the following treatment strategies; levetiracetam, lamotrigine, 
carbamazepine, phenytoin and valproate. The iterations each had four Markov states; 
controlled on treatment, controlled off treatment, uncontrolled and dead. The structure of the 
model was based on literature and validated through expert opinion. Each state had an 
associated HRQoL measure which was obtained from literature (3). Transition probabilities 
were used to describe all possible movements between the Markov states after each cycle and 
were calculated based on literature findings. A time horizon of five years and a cycle length of 
six months were used to capture movement between the Markov states. A 3% discount rate on 
both costs and effects was used for each subsequent year after the first year of treatment as 
stipulated by the IDSI reference case (29). Based on the outcome values, the interventions were 
listed from least expensive to most expensive to determine if there were any strategies that 
incur higher costs but provided lower effects (i.e. dominated strategies). These strategies were 
excluded from the analysis. Incremental Cost-Effectiveness Ratios (ICERs) were calculated for 
the appropriate strategies, using the previous less costly treatment strategy for comparison. 
Results were presented in tabular form and on a cost-effectiveness plane. Incremental Cost-
Effectiveness Ratios were calculated using the following formula; 
ICER =  
(     )   (     )  ( )
(  )   (  )  ( )
 









Figure 2: Structure of the Markov model. 
 
Budget impact analysis 
A budget impact analysis was conducted for each of the five strategies from the providers’ 
perspective over a one-year period. The target population was adult patients with newly 
diagnosed epilepsy who are serviced by the public sector. This population was estimated by 
multiplying the estimated adult population size obtained from Statistics South Africa by the 
estimated incidence rate of epilepsy in South Africa and the estimated percentage of the 
population that is serviced by the public sector (34)(6). Utilization rates were incorporated in 
the calculation of both pharmaceutical costs and costs to the health system. The five treatment 
strategies were treated as mutually exclusive in the analysis. Results were presented in tabular 
form as the total pharmaceutical, non-pharmaceutical and health systems costs for adopting 



























Figure 3: Framework to estimate budget impact of introducing levetiracetam to the South African public health system for 
the treatment of epilepsy. 
Model inputs  
Clinical inputs 
Probability table 
Transition probabilities for death, remission and relapse were obtained from literature. The 
transition probabilities for a patient remaining controlled were calculated through the 
multiplication of hazard ratios of the comparator treatment strategies relative to levetiracetam 
obtained from the Adult ERC LEV MR and the “seizure freedom” proportion obtained from 
the levetiracetam trial. The rest of the transition probabilities were obtained using probability 
tables given the condition that the transition probabilities associated with each Markov state 
must add up to a value of 1. 
Description Value Source 
Probability of death when uncontrolled 0,01085 3.1*Population death-rate 
Wagner (2015) reported that the risk of mortality for 
people whose epilepsy is uncontrolled is 3.1 times 




Minus cost offsets (positive and 
negative clinical events) 
Carbamazepine 






Budget Impact estimate 
Figure 3: Framework to estimate budget impact of introducing levetiracetam to the South African public health system for the 





Probability of going from ‘controlled on 
treatment’ to ‘controlled off treatment’  
0,0425 Wagner (2015) 
(6) 
Probability of remaining uncontrolled 0,98915 Calculated through probability panel (probabilities 
leaving each health state must add up to 1) 
Probability of remaining ‘controlled off 
treatment’  
0,98915 Wagner (2015) 
(6) 
Probability of staying ‘controlled on 
treatment’ for LEV 
0,43884 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (35).  
Probability of going from ‘controlled on 
treatment’ to ‘uncontrolled’ on LEV 
0,51516 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of staying ‘controlled on 
treatment’ for LTG 
0,5019 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of going from ‘controlled on 
treatment’ to ‘uncontrolled’ on LTG 
0,4521 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of staying ‘controlled on 
treatment’ for VPA 
0,34344 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of going from ‘controlled on 
treatment’ to ‘uncontrolled’ on VPA 
0,61056 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of staying ‘controlled on 
treatment’ for PHT 
0,34344 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of going from ‘controlled on 
treatment’ to ‘uncontrolled’ on PHT 
0,61056 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of staying ‘controlled on 
treatment’ for CBZ 
0,34344 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of going from ‘controlled on 
treatment’ to ‘uncontrolled’ on CBZ 
0,61056 Adult ERC Lev MR and Seizure free proportions from 
LEV trial (27) 
Probability of death when controlled on 
treatment/controlled off treatment 
(underlying mortality) 
0,0035 Average age specific death rate for the median age-
group in South Africa (25 years-30 years)  
WHO (2018)  
(36) 
Table 1:  Key clinical inputs. 
 
Utilities 
The long-term outcomes associated with each treatment regimen were calculated by applying 





in the model. The annual utilities which accrued to an epileptic patient are detailed in the table 
below, with death incurring no utility.  
Health State HRQoL Value Source 
Controlled on treatment 0,94 Wilby et al (2003) 
(16) 
Controlled off treatment 0,94 Wilby et al (2003) 
(16) 
Uncontrolled (Second Line) 0,84 Wilby et al (2003) 
(16) 
Dead 0  
Table 2:  Utility values for each Markov state. 
Cost inputs 
The main costs included in both the budget impact analysis and the cost effectiveness analysis 
were associated with the drug procurement costs of the AEDs, drug titration for some treatment 
options and the hospital costs associated with the treatment of seizures and related events. Costs 
associated with the diagnosis of epilepsy were not included in the analysis as they would be 
common to all patients regardless of the resulting treatment choice. Costs were categorized 
based on whether the patient was controlled or uncontrolled due to the varying utilization rates 
(3). Per patient costs were calculated by multiplying unit costs by utilization rates. 
Utilization rates were obtained from the study by Wilby et al (2005) (3). The average per patient 
values were calculated by multiplying the expected value for utilization by the probability of 
use of the services for each patient which was based on seizure freedom status. The number of 
hospital visits associated with each titration period was based on STG recommendations. 
DESCRIPTION PROBABILITY  VALUE 
Inpatient days when controlled 0,01 0,01 
Inpatient days when uncontrolled 0,16 0,16 
Average length of stay controlled 1,00 5,6 
Average length of stay uncontrolled 1,00 8,9 
Outpatient visits when controlled 0,18 0,54 
Outpatient visits when uncontrolled 0,42 1,26 
Emergency room visits controlled 0,02 0,02 
Emergency room visits uncontrolled 0,23 0,23 
Visits for medication collection 1,00 12 
Hospital visits for lamotrigine titration 1,00 6 
Hospital visits for carbamazepine 
titration 
1,00 3 
Hospital visits for valproate titration 1,00 2 



















Estimated cost for 
inpatient visits when 
controlled 
R2 803,00 0,056 R156,97 R78,48 Health Systems Trust 
(33) and Wilby et al 
(2005) (3) 
Estimated cost for 
inpatient visits when 
uncontrolled 
R2 803,00 1,424 R3 991,47 R1 995,74 Health Systems Trust 
(33) and Wilby et al 
(2005) (3) 
Estimated cost for 
outpatient visits when 
controlled 
R450,00 0,54 R243,00 R121,50 Health Systems Trust 
(33) and Wilby et al 
(2005) (3) 
Estimated cost for 
outpatient visits when 
uncontrolled 
R450,00 1,26 R567,00 R283,50 Health Systems Trust 
(33)  and Wilby et al 
(2005) (3) 
Estimated cost 
emergency room visits 
when controlled 
R4 382,88 0,02 R87,66 R43,83 Health Systems Trust 
(33)  and Wilby et al 
(2005) (3) 
Estimated cost 
emergency room visits 
when uncontrolled 
R4 382,88 0,23 R1 008,06 R504,03 Health Systems Trust 
(33) and Wilby et al 
(2005) (3) 
Estimated cost for AED 
visits 
R32,00 12 R384,00 R192,00 Administration 
Pharmacy Cost 
multiplied by 
number of monthly 
visits 
Estimated total cost for 
lamotrigine titration  
R38,67 6 R232,02 R232,02 Pharmaceutical costs 




Estimated total cost for 
carbamazepine titration 
R38,67 3 R116,01 R116,01 Pharmaceutical costs 
based on STG 
recommendations 
Estimated total cost for 
valproate titration 
R38,67 2 R77,34 R77,34 Pharmaceutical costs 
based on STG 
recommendations 
Table 4: Cost Inputs for the models. 
The percentage risk for Steven-Johnson Syndrome was obtained from literature. Treatment of 
each case of Steven-Johnson Syndrome was estimated to cost  R65 855,00 to the health 
system based on a study conducted in Thailand (20). This value was obtained by applying the 
2013 US$ to ZAR exchange rate on the value obtained from the study followed by inflating 
the value to its South African 2018-rand value (37). The estimated annual cost per patient 








0,01 R6,59 UCB Pharma Limited 
(2019) (35)  
Frey et al (2017) 
 (38) 






Lamotrigine 0,05 R29,63 Frey et al (2017) 
 (38)  
Phenytoin 0,05 R29,63 Frey et al (2017) 
 (38)  
Valproate 
  
0,00 R0,00  
Table 5: Per patient cost of treating Steven-Johnson Syndrome.  
Pharmaceutical costs were calculated based on the 2018 tender prices for each drug as informed by the 
Master Procurement Catalogue (39). The values for “cost per patient for first six months of treatment” 
incorporated titration schedules as informed by the Standard Treatment Guidelines (STGs) were 



































Levetiracetam 3000 750 4 R3,07 112 R343,84 R2 063,04 R4 126,08 Master Procurement 
Catalogue 1 June 2018 
Carbamazepine 1200 200 6 R0,31 168 R51,74 R305,97 R616,43 Master Procurement 
Catalogue 1 June 2018 
Lamotrigine 300 100 3 R0,90 84 R75,60 R330,40 R784,00 Master Procurement 
Catalogue 1 June 2018 
Phenytoin 300 100 3 R0,86 84 R72,24 R433,44 R866,88 Master Procurement 
Catalogue 1 June 2018 
Valproate 1500 500 3 R0,79 84 R66,36 R402,64 R800,80 Master Procurement 
Catalogue 1 June 2018 
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Table 7: Pharmaceutical costs over titration period. 
The cumulative costs for each Markov health state where calculated as shown in the table 
below. 
Markov State Cost Calculation 
Controlled on treatment (Pharmaceutical costs + Non-pharmaceutical costs + Cost of 
treating Steven-Johnson Syndrome) * Probability of patient 
being in the “controlled on treatment” state 
 
Controlled off treatment 
(Non-pharmaceutical costs) * Probability of patient being in the 
“controlled off treatment” state 
Uncontrolled 
 
(A flat fee of R5 000 was added to the non-pharmaceutical costs 
associated with the uncontrolled state) * Probability of patient 
being in the “uncontrolled” state 
Dead (Patients in the dead state incurred no costs) * Probability of 
patient being dead 
Table 8: Calculations for costs associated with the Markov model. 
 
Model assumptions for both the CEA and BIA 
 The cost per emergency room visit is 1.5 times the cost per “Patient Day 
Equivalence” (PDE) and the cost per inpatient day is equal to the cost per PDE 
 In the treatment of status epilepticus, seizures are under control after 2 doses of 
lorazepam and one dose of phenytoin (based on the Standard Treatment Guidelines) 
 Side-effects associated with AED treatment disappear when treatment is stopped, 
requiring no further treatment, except for Steven-Johnson Syndrome 
 The seizure freedom rate provided in the levetiracetam clinical trial was obtained 
from the start of the trial 
 The proportion of HIV positive patients is evenly distributed among the various 
Markov states, therefore has no impact on the resulting ICER values 
 Patients cannot move “back” to controlled from uncontrolled as the uncontrolled state 
is intended to be a broad classification representing costs and health of those that have 






Sensitivity analyses were conducted to address uncertainty for the cost-effectiveness analysis 
using the outputs of the decision-tree. Sensitivity analysis was conducted on parameters 
considered to have a large impact on the ICER values obtained in the decision-tree model. 
Levetiracetam was compared to lamotrigine, which was found to be the dominating strategy in 
the main analysis. A limitation of one-way sensitivity analysis is that the parameters rarely 
move independently of each other, limiting the number of parameters that could be included in 
the analysis. The cost values for carbamazepine, lamotrigine, phenytoin and valproate were not 
included as they were considered fixed based on tender prices. More complex sensitivity 
analysis, (e.g. probabilistic sensitivity analysis) was beyond the scope of this study. The results 
obtained were presented in the form of a tornado diagram. 
RESULTS 
Cost-effectiveness analysis 
The expected cost of treatment for a single case of epilepsy over a five-year period was found 
to range from R63 567 with lamotrigine to R66 970 with carbamazepine. The expected effect 
size was between 4,01 QALYs and 3,97 QALYs. The use of levetiracetam along with the use 
of phenytoin, valproate and carbamazepine in the treatment of newly diagnosed epilepsy was 
found to be dominated by treatment using lamotrigine. A dominated strategy is defined as one 
which costs comparatively more but has a lower health effect (40). Treatment with lamotrigine 
over a five-year period was found to be the least costly treatment option and had the highest 
number of QALYs gained. The estimated cost of treating one case of epilepsy was R1 252 
higher using levetiracetam compared to using lamotrigine. Levetiracetam had 0,02 QALYs 
lower than those of lamotrigine. Phenytoin, carbamazepine and valproate were found to have 







Lamotrigine R63 567 4,01  
Levetiracetam R64 819 3,99 Dominated 
Phenytoin R66 023 3,97 Dominated 
Valproate R66 550 3,97 Dominated 
Carbamazepine R66 970 3,97 Dominated 






Figure 4: Cost-effectiveness plane for the first-line treatment of epilepsy with levetiracetam. 
Sensitivity analysis 
Both the levetiracetam-related costs used in the sensitivity analyses showed that lower cost 
values were associated with less negative ICER values (i.e. levetiracetam became 
comparatively more cost-effective as the levetiracetam-related costs became lower). There 
were no trends observed regarding the impact of the quality of life measures on the ICER values 
obtained and the probability of remaining controlled on levetiracetam. 
Parameter Lower Value Baseline Upper Value 
HRQoL when "uncontrolled" 0,50 0,84 0,95 
HRQoL when "controlled on 
treatment" 
0,70 0,94 1,0 








LEV unit cost R1,54 R3,07 R4,61 
Controlled on treatment (LEV) 0,33884 0,43884 0,53884 
Table 10: Values used for the decision-tree sensitivity analyses. 
 
ICER at lower parameter 
value  
ICER at higher parameter 
value 
HRQoL when "uncontrolled" -R116 856 R5 130 201 
 
HRQoL when "controlled on 
treatment" 
R213 303  -R186 624 
 
LEV- cost input for "controlled 
on treatment" 
-R130 816  -R466 406  
LEV unit cost -R161 711  -R456 208  
Controlled on treatment (LEV) -R187 062 R232 642 
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Figure 5: Tornado plot for sensitivity analyses. 
 
Budget impact analysis 
The population of interest, which was the number of adult patients with newly diagnosed 
epilepsy serviced by the South African public health sector was calculated by multiplying the 
estimated incidence rate by the estimated adult population of South Africa and the estimated 
proportion of South African serviced by the public health sector. 
Parameter Value Source 




Estimated incidence rate 0,0174% Wagner (2015) 
(6) 
Estimated proportion of South Africans 







Estimated population of interest 5 689 
 
Table 12: Calculation for the estimated population of interest. 
The pharmaceutical costs of treating newly diagnosed epilepsy with levetiracetam were found 
to be higher in comparison to those of comparators. For a 100% treatment coverage, the cost 
of treatment with lamotrigine, the other second-generation AED under analysis was about R19 
million cheaper compared to treatment with levetiracetam over a one-year period. Treatment 
with carbamazepine was found to be the cheapest option, costing about R20 million less than 
-R500 000,00 R500 000,00 R1 500 000,00 R2 500 000,00 R3 500 000,00
LEV-input for "controlled on treatment"
LEV unit cost
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treatment with levetiracetam. The trends observed under 100% treatment coverage were also 
observed at 80%, 50% and 10% treatment coverage.  
 Coverage (%) 100% 80% 50% 10% 
Coverage 
 (no of patients) 







Levetiracetam R23 473 759 R18 779 007 R11 736 879 R2 347 376 
Carbamazepine R3 423 336 R2 738 669 R1 711 668 R342 334 
Lamotrigine R4 453 101 R3 562 481 R2 226 550 R445 310 
Phenytoin R4 931 783 R3 945 427 R2 465 892 R493 178 
Valproate R4 530 359 R3 624 287 R2 265 180 R453 036 
Table 13: Budget Impact Analysis for pharmaceutical costs in first line treatment of epilepsy.  
Levetiracetam would still be the most expensive treatment option even with a 50% price 
reduction while maintaining the prices of the other drugs. 







Levetiracetam R11 736 880 R23 473 759 R35 210 638 
Carbamazepine R3 506 966 R3 506 966 R3 506 966 
Lamotrigine R4 632 308 R4 632 308 R4 632 308 
Phenytoin R3 469 452 R3 469 452 R3 469 452 
Valproate R5 396 926 R5 396 926 R5 396 926 
Table14: Budget Impact Analysis sensitivity analysis for the cost of levetiracetam in the first-line treatment of epilepsy. 
Lamotrigine incurred the least non-pharmaceutical costs associated with epilepsy treatment, 
followed by levetiracetam, with a difference of R546 886. Carbamazepine incurred the highest 
costs, followed by valproate. The trends observed at a 100% coverage were also observed at 
80%, 50% and 10% coverage. 
 Coverage (%) 100% 80% 50% 10% 
Coverage  
(no of patients) 








Levetiracetam  R20 518 480 R16 414 784 R10 259 240 R2 051 848 
Carbamazepine 
  
R24 244 183 R19 395 346 R12 122 091 R2 424 418 
Lamotrigine 
  
R19 971 594 R15 977 275 R9 985 797 R1 997 159 
Phenytoin 
  
R23 584 188 R18 867 350 R11 792 094 R2 358 419 
Valproate  R24 024 184 R19 219 348 R12 012 092 R2 402 418 





A reduction in the differences in cost between treatment with levetiracetam and the comparator 
drugs was observed on inclusion of other health systems costs associated with the treatment of 
epilepsy, such as the cost of treating Steven-Johnson Syndrome and non-pharmaceutical costs 
associated with seizure treatment (e.g. inpatient days, emergency room stays, outpatient days 
and AED collection visits). Levetiracetam was still found to be the costliest treatment option 
costing about R44 million to the health system and lamotrigine was found to be the least costly 
treatment option costing about R25 million to the health system. Non-pharmaceutical costs 
were found to be the cost drivers in the analysis for all the treatment options, except for 
treatment with levetiracetam. Pharmaceutical costs accounted for 53,3% of the levetiracetam 
treatment costs. 
 Coverage (%) 100% 80% 50% 10% 
Coverage  
(no of patients) 







Levetiracetam R44 041 937 R35 233 549 R22 020 968 R4 404 194 
Carbamazepine R27 757 093 R22 205 674 R13 878 546 R2 775 709 
Lamotrigine R24 604 055 R19 683 244 R12 302 028 R2 460 406 
Phenytoin R28 699 209 R22 959 367 R14 349 605 R2 869 921 
Valproate R25 063 481 R20 050 785 R12 531 741 R2 506 348 
Table 16: Budget Impact Analysis for health systems costs from the providers’ perspective in first-line treatment of epilepsy. 
DISCUSSION 
This study was the first cost-effectiveness analysis of anti-epileptic drugs in the South African 
context and will likely impact the Standard Treatment Guidelines for the first-line treatment of 
epilepsy in South Africa positively impacting the lives of adult epileptics. The study also 
contained a Budget Impact Analysis, providing policy makers with budgetary estimates for the 
implementation of the various treatment options. 
Key limitations of this analysis include the absence of context specific effect measures and 
context specific utilization rates. This leads to the assumption that utilization rates in a LMIC 
like South Africa are the same as those observed in high income countries from which the data 
on utilization rates was obtained.  
The effect sizes of all the treatments under analysis were similar, with a difference of 0,04 
QALYs between the most effective and the least effective treatment option. First generation 
AEDs had the same effect value and higher associated costs in the five years of treatment 





resulting ICER values. Approximately a 93% price reduction is required for levetiracetam to 
be more cost-effective than lamotrigine. 
The cost of treating Steven-Johnson Syndrome was also included in the analysis, with a single 
case costing R65 855, but due to the low prevalence of the condition, this cost had a lower 
impact on the ICER values compared to pharmaceutical costs. Valproate did not incur the costs 
associated with the treatment of this side effect. Although lamotrigine incurred the cost of 
treating Steven-Johnson Syndrome, the drug still had the lowest health systems costs. This is 
due to the higher effectiveness of the drug, which leads to lower costs incurred on treatment of 
seizures.  
Cost-minimization studies conducted in Europe by Heaney et al (2000) found that the direct 
costs of using lamotrigine in the treatment of newly diagnosed epilepsy were higher than those 
of using carbamazepine, valproate and phenytoin (41). These finding are not consistent with 
the findings from the budget impact analysis of this study, which found that the use of 
lamotrigine incurred the least health systems cost compared to the first-generation AEDs. This 
highlights the differences in context and pricing, further indicating that the use of studies 
conducted in developed countries over a different time-period to inform decisions in 
developing countries may not be appropriate.  
An assumption was made in this analysis that the “uncontrolled” state is a broad classification 
representing the costs and health of patients who have failed first-line treatment. All patients 
in this state where considered to incur the same cost related to treatment which may not be an 
accurate depiction of clinical practice, as various options of treatment are available as second-
line treatment and beyond. Analysis of costs and health effects associated with treatment post 
first-line treatment was beyond the scope of this study. 
The effect measures for the study were determined by the probabilities of seizure control and 
the HRQoL measures. The HRQoL values were obtained from a study conducted in the United 
Kingdom, introducing uncertainty into the analysis due to differences in context which may 
impact some domains related to quality of life. The impact of this on the study findings was 
investigated through sensitivity analysis. The quality of life measures included in the sensitivity 
analysis showed no trends with regards to the resulting ICERs. Changes in the quality of life 
values for both the “uncontrolled” and “controlled on treatment” groups impacted both 
levetiracetam and lamotrigine, though to different extents. The lower quality of life value for 





the negative incremental effect observed due to the comparatively lower proportion of patients 
in the “controlled on treatment” group for the levetiracetam treatment strategy. The upper 
quality of life value for the “uncontrolled” group also resulted in a positive ICER for 
levetiracetam due to the negative incremental effect observed due to the comparatively higher 
proportion of patients in the “uncontrolled” group for levetiracetam. No trends were observed 
due to changes in the ICER sign associated with varying the HRQoL values and the varying 
impact of the HRQoL values on both the treatment options under analysis. An increase in the 
probability of remaining controlled on treatment whilst on levetiracetam was associated with 
an increase in effect size and a decrease in costs. Although this was observed, there was no 
trend regarding the ICER values as the change in probability affected both the costs and effects 
associated with levetiracetam treatment disproportionately. 
The model results for the cost-effectiveness analysis agree with the study by Wilby et al (2005), 
which was conducted to inform the NICE treatment guidelines, which found that levetiracetam 
was not cost-effective (42). The study conducted by the Scottish Intercollegiate Guidelines 
Network (SIGN) was non-conclusive with regards to the cost-effectiveness of levetiracetam. 
Lamotrigine is recommended for the treatment of both partial and generalized tonic-clonic 
seizures by both NICE and SIGN (43)(42). It is the only drug recommended for the treatment 
of both indications, with carbamazepine also being recommended for the treatment of partial 
seizures and valproate for the treatment of generalized tonic-clonic seizures.  
The absence of a South African specific ICER threshold prevents conclusion in absolute terms 
on the cost-effectiveness of any of the treatment options. The threshold represents willingness 
to pay and is ideally the ICER value of the last funded intervention in the health sector. 
The budget impact analysis was conducted based on the estimated incidence of epilepsy in 
South Africa and the estimated utilization rate for public sector services of 84%. The budget 
impact analysis was conducted at two levels. The first level only considered pharmaceutical 
costs and levetiracetam was found to be the costliest treatment option, while carbamazepine 
was found to be the least costly treatment option. The pharmaceutical costs used for this study 
were solely obtained from tender prices unique to the South African public sector, limiting the 
generalizability of the results obtained in this study to other contexts. Even when the price of 
levetiracetam is lowered to 50%, treatment with levetiracetam is still more costly than the other 
available options. On inclusion of other health systems costs associated with the treatment of 





treatment option. This demonstrates its higher effect size which is associated with a lower cost 
of treatment for seizures. Levetiracetam was still found to be the most expensive treatment 
option on inclusion of other health systems costs in the budget impact analysis, costing the 
health system almost double the amount it would cost for treatment with lamotrigine. Given 
the higher effect size of lamotrigine and the high demand for resources in the South African 
health sector due to the quadruple burden of diseases, the use of lamotrigine as first line 
treatment for epilepsy would be most appropriate.  
The introduction of cost-effective epilepsy treatment must be accompanied by patient 
education in the South African context to maximise health outcomes through improved patient 
adherence. There is also need to address the combined use of Western medicines with 
traditional treatments, mostly in rural areas, which may negatively impact treatment outcomes 
(24). Community education must also be introduced in order to tackle the stigma associated 
with epilepsy so as to improve utilization rates of epilepsy treatment and seizure prophylaxis 
(7). Further studies to differentiate the cost-effectiveness of levetiracetam in comparison to 
lamotrigine in rural areas versus in urban areas given the differences in access to health care 
services which may impact the titration of lamotrigine may also be necessary. There is also 
need for further studies examining the characteristics of the health care system that contribute 
to the epilepsy treatment gap. To improve the accuracy of future cost-effectiveness analysis, 
there is need to invest in epidemiological studies to inform context specific burden of disease 
and service utilization rates. 
CONCLUSION 
Based on the findings of the study and recommendations from international organizations, 
lamotrigine would be the most cost-effective first line treatment of newly diagnosed epilepsy, 
even when accounting for the titration period associated with this drug and the associated risk 
of Steven-Johnson Syndrome as a side-effect. It is effective in the treatment of both partial 
seizures and generalized tonic-clonic seizures. For levetiracetam to be more cost-effective than 
lamotrigine, a price decrease of 93% is required, which is unlikely given that the South African 
Department of Health already has the drug on tender. There is need for further research on the 
cost-effectiveness of levetiracetam in the treatment of specific sub-groups in the epileptic 
population such as pregnant women, lactating women, the elderly, those who are HIV positive 





LIMITATIONS OF THE STUDY 
 The translation of “time to seizure-freedom” which was the primary outcome measure 
for the Adult ERC Lev MR into transition probabilities for the cost-effectiveness 
analysis. 
 Data on effectiveness was obtained from multiple studies, therefore there was indirect 
comparison of the drugs under analysis. 
 A systematic review of the literature on economic evaluations for epilepsy to determine 
model input parameters is preferred but was not conducted due to resource limitations.  
 Some of the model parameters used were not specific to the South African context. 
 Assumptions were made in the modelling process which may not be representative of 
the heterogenous patterns seen in clinical practice. 
 Analysis did not consider the impact of co-morbidities on the choice of treatment for 
epilepsy. 
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Epilepsy is a condition associated with the occurrence of seizures and it is estimated that 1% 
of South Africans have this condition. The condition is primarily managed through seizure 
prevention using medicines called anti-epileptics. The anti-epileptic drugs (AEDs) currently 
used in South Africa after an initial epilepsy diagnosis are carbamazepine, lamotrigine and 
phenytoin. Valproate is sometimes used in practice for patients with a new epilepsy diagnosis. 
Levetiracetam is under consideration as a replacement for the above stated medicines in the 
treatment of partial and generalized seizures because of its reported ease of use for both patients 
and health care professionals. It has also been reported that levetiracetam has less serious side 
effects compared to the other available medicines. This study was carried out to determine if 
levetiracetam is more cost-effective in comparison to the medicines currently used in practice 
over five years to ensure the efficient allocation of resources in the health sector. This was done 
by conducting a cost-effectiveness analysis. A cost-effective treatment is one which provides 
relatively good value for money. The study was carried out by comparing the costs and health 
effects of the medicines under analysis. Health effects were measured as Quality Adjusted Life-
Years (QALYs), which represent both the number of years lived by the patient and their quality 
of life over those years. Costs were presented as the South African Rand, 2018 value. The study 
was conducted from the perspective of the South African public health sector. Lamotrigine was 
found to be the most cost-effective treatment option over a five-year period. It had the lowest 
cost of treatment and the highest health effects. The estimated cost of treating one case of 
epilepsy was R1 252 higher using levetiracetam compared to using lamotrigine. Levetiracetam 
had 0,02 QALYs lower than those of lamotrigine. Phenytoin, carbamazepine and valproate had 





of treatment for each of the medicines under analysis over the first year of treatment through a 
budget impact analysis. Levetiracetam was found to incur the highest cost of treatment both 
when only considering the cost of purchasing the medicine for treatment and when considering 
the total cost of treatment to the health care system. Treatment with levetiracetam was found 
to cost about R44 million to the health system and treatment with lamotrigine was found to be 
the least costly option costing about R25 million to the health system. Levetiracetam was not 
found to be cost-effective as the initial treatment for epilepsy in the South African public health 
sector. For levetiracetam to be cost-effective, a price reduction of 93% is required. Following 
the findings of this study, lamotrigine is recommended as the first-line treatment for epilepsy 
associated with generalized tonic-clonic seizures and partial seizures. 
INTRODUCTION 
 
Epilepsy is a chronic condition of the nervous system that affects approximately 560,000 
people in South Africa (1). The condition results in seizures which may or may not lead to loss 
of consciousness (2). It is associated with considerable disability in patients who are 
uncontrolled and can lead to premature death (3)(4). Underlying causes of epilepsy include 
head injuries, drug and alcohol abuse and infectious diseases such as HIV/AIDS and 
tuberculosis (5)(2). Causes in South Africa are likely to be infectious due to the high HIV and 
tuberculosis prevalence (5). Epilepsy also has a negative impact on the quality of life of patients 
living with the disease as it affects their psychological wellbeing (6). Frequency and severity 
of seizures, depression usually associated with uncontrolled epilepsy and side-effects due to 
AEDs all contribute to a reduced quality of life (7)(6). Individuals with epilepsy are 
significantly more likely to have a mood disorder compared to the general population, with 





Adequate seizure control can result in an improved quality of life especially due to improved 
social function (6). Epilepsy is also associated with high levels of stigma in the African context, 
especially in rural areas due to a belief that the disease is contagious and a result of a curse (4). 
The disease has significant negative economic effects at both individual and societal level. At 
individual level, costs range from those directly associated with treatment such as the cost of 
medicines for the prevention and treatment of seizures to the loss of income due to the lower 
productivity associated with illness (4). At national level some countries spend as much as 1% 
of their total health care expenditure on epilepsy treatment, signifying the economic burden of 
the disease (4). The estimated percentage of the global burden of disease associated with 
epilepsy in developing countries is about 90%, while only 20% of all epilepsy related health 
expenditure is spent in developing countries (9). This, together with other factors such as poor 
infrastructure and scarcity of trained medical staff, has resulted in an estimated 75% of 
epileptics in developing countries not receiving treatment (10). To ensure that the money spent 
on epilepsy treatment in developing countries is used efficiently, there is need to conduct 
economic evaluations to ensure that cost-effective treatments are funded. This is especially 
important in the context of South Africa were the public health sector is strained due to the 
quadruple burden of disease (11). An economic evaluation is defined as the comparative 
analysis of alternative courses of action in terms of costs and effects (12). 
Epilepsy has multiple treatments which include; the use of medicines, surgery, 
neurostimulation and the ketogenic diet. Surgery and neurostimulation are usually used when 
the individual is not responsive to medicines used in preventing seizures (13)(14). The 
ketogenic diet, which is a low-carbohydrate, adequate protein and high-fat diet has been 
established as an effective option for managing refractory epilepsy in children between the ages 





seizures using AEDs. Use of a single AED compared to multiple AEDs is advised to limit side 
effects associated with treatment (16). AEDs can be divided into first- and second-generation 
drugs. Phenytoin, valproate and carbamazepine are first-generation, while lamotrigine and 
levetiracetam are second-generation AEDs (17). Second-generation AEDs have been found to 
be safer for patients compared to first-generation AEDs, although they cost more (17). Some 
AEDs such as phenytoin, carbamazepine, levetiracetam and lamotrigine may cause intense 
allergic reactions in patients who are susceptible, for example those with a weakened immune 
system due to HIV (18). Hypersensitive reactions includes Steven Johnson Syndrome which is 
a rare but serious disorder of the skin associated with painful red blisters and can lead to death 
(19). Phenytoin and carbamazepine increase the rate at which hormonal contraceptives are 
cleared from the body, potentially rendering them ineffective (20). This is especially a problem 
if pregnancy occurs during the use of phenytoin as it can lead to foetal malformation (20). Use 
of valproate during pregnancy is also associated with malformations during foetal development 
(20). Lamotrigine, together with carbamazepine and valproate require a gradual increase in 
dose until the optimum dose is reached on treatment initiation in order to minimize the 
occurrence of side-effects (21). This process results in an increased cost of treatment due to the 
increased number of hospital visits (21). The blood levels lower than the effective threshold 
during the dose adjustment period may also lead to breakthrough seizures, further increasing 
treatment costs (21). 
The current first-line treatment of epilepsy on diagnosis in South Africa is lamotrigine, 
phenytoin or carbamazepine (22)(23). Valproate is occasionally used in practice. 
Levetiracetam is under consideration for inclusion on the South African Essential Medicines 





treatment options (24). It is crucial to determine the cost-effectiveness of these available AED 
options in South Africa to ensure the efficient use of the limited resources for health.  
RESEARCH OBJECTIVE 
 
The study assessed the cost-effectiveness of levetiracetam compared to the other available 
treatment options in the South African public health sector which are lamotrigine, 
carbamazepine, phenytoin and valproate over a five-year period. This was achieved using a 
cost-effectiveness analysis. The study also assessed the cost of treatment using each of the five 
AEDs under analysis for the first year of treatment. This was achieved through a budget impact 
analysis. Use of the AEDs was considered to be mutually exclusive in this study. 
What is a cost-effectiveness analysis? 
 A cost-effectiveness analysis compares the costs and effects associated with different 
treatment interventions over a set period through the generation of incremental cost-
effectiveness ratios (ICERs). 
 ICERs are ratios of incremental costs and incremental effects of the available treatment 
options. Before ICERs can be calculated, the treatment options must be listed from least 
costly to most costly. Interventions that cost more but have lower effect sizes are 
“dominated” and are excluded from the analysis. ICERs are calculated for the appropriate 
strategy using the previous less costly treatment strategy for comparison. 
 Interventions with low ICER values are usually preferred compared to those with higher 
ICER values because of their lower additional cost per additional unit of effect. 
 A country threshold in the form of the cost of the last fully funded health care intervention 






What is a budget impact analysis? 
 A budget impact analysis is an estimate of the cost of introducing an intervention in the 
health system. 
 The costs directly associated with the resources needed for the introduction of the 
intervention to the health care sector are added up. 
 These costs can include the cost of medicines, the cost of services provided along with 
the intervention and the costs of treating side effects that can occur due to the treatment 
option. 
 The analysis considers the proportion of the population that will have access to the 




Both the budget impact analysis and the cost-effectiveness analysis were conducted from a 
providers’ perspective in the provision of care to newly diagnosed adult epilepsy patients in 
the public sector. This means that only costs directly incurred by the South African public 
health sector in introducing and offering each intervention were collected for the analysis. The 
study utilized secondary data and the estimated input costs and effects of the treatment options 
were obtained from literature. No primary data was collected or used. Where possible, input 
values specific to South Africa were used. The outputs for the study were estimated using 
models based on the Standard Treatment Guidelines and literature findings. The budget impact 





the first five years of treatment. Costs were presented as the South African Rand; 2018 value 
and effects were expressed as QALYs. Costs used in the analysis include the pharmaceutical 
costs associated with treatment, costs associated with the treatment of expected seizures over 
the treatment period and the treatment cost of Steven Johnson Syndrome. Steven Johnson 
Syndrome is a hyperallergic reaction that may occur in patients taking lamotrigine, 
carbamazepine and phenytoin. QALYs measure the years of life lived by the patient adjusted 
by a quality of life measure. A perfectly healthy patient over a one-year period has a QALY 
value of 1 and the QALY value for death is O. Quality of life measures were based on the 
patients’ seizure freedom status. Patients experiencing seizures were considered to have a lower 
quality of life measure compared to patients without seizures. The effect size for each treatment 
option was based on the probability of a patient becoming seizure-free on that treatment. 
Treatments that had a higher probability of leading to a seizure-freedom state in patients had a 
higher effect size. The costs and cost-effectiveness of treatment with levetiracetam for patients 
with newly diagnosed epilepsy were compared to treatment with lamotrigine, carbamazepine, 
phenytoin and valproate. Sensitivity analyses on costs associated with treatment using 
levetiracetam and some quality of life measures were also conducted for the first 6 months of 
treatment to address uncertainty with regards to the cost-effectiveness analysis. The costs used 
for the sensitivity analysis were the unit cost of levetiracetam and the total treatment cost for a 
patient on levetiracetam over six months. The quality of life measures used were those of 










 Seizure-free patients incurred lower costs compared to patients who had seizures due 
to their lower utilization of health care resources. 
 Treatment with lamotrigine incurred the lowest cost and had the highest number of 
QALYs gained compared to levetiracetam, carbamazepine, phenytoin and valproate. 
Lamotrigine was therefore the most cost-effective treatment option. 
 The cost of treating a single case of epilepsy over five years ranged from R63 567 using 
lamotrigine to R66 970 using carbamazepine.  
 Effect size ranged between 4,01 QALYs for lamotrigine and 3,907 QALYs for 
valproate, carbamazepine and phenytoin. Lamotrigine therefore had the highest effect 
size. 
  Levetiracetam treatment resulted in a gain of 3,99 QALYs.  
 The other treatment options were dominated by lamotrigine, therefore ICERs were not 
calculated. A dominated strategy is one which costs more but has a lower effect size 
(25).  
 The findings of the sensitivity analysis showed that lowering both the cost of purchase 
for levetiracetam and the total cost associated with treatment using levetiracetam 
resulted in levetiracetam becoming comparatively more cost-effective compared to 
lamotrigine.  
 For levetiracetam to become more cost-effectiveness than lamotrigine, a price reduction 





 Quality of life measures were also varied as part of sensitivity analysis, but no trends 
regarding the relationship between the quality of life measures and the comparative 
cost-effectiveness of levetiracetam were observed. 
 The probability of remaining controlled on levetiracetam was also varied and no trend 
on the resulting ICER values was observed. 
 
Figure 1: Comparison of costs and effects of the treatment options. 
 
Budget impact analysis 
 The cost of purchasing levetiracetam was found to be higher than that of purchasing the 
other comparators, costing R23,5 million. 
 Treatment with carbamazepine was the cheapest option, costing about R20 million less 
than treatment with levetiracetam. 
 Levetiracetam would still be the most expensive treatment option even with a 50% 
price reduction while maintaining the prices of the other drugs. 
 The cost of purchasing levetiracetam accounted for 53,3% of the total cost of treating 




















Comparison of costs and effects for epilepsy 
treatments





 Levetiracetam was still the costliest treatment option on inclusion of other health 
systems costs such as the cost of treating Steven-Johnson Syndrome and non-
pharmaceutical costs associated with seizure treatment, costing about R44 million to 
the health system and lamotrigine was found to be the least costly treatment option 
costing about R25 million to the health system. 
 Treatment with lamotrigine incurred the least non-pharmaceutical costs associated 
with epilepsy treatment, followed by levetiracetam, with a difference of R546 886. 
Carbamazepine incurred the highest costs, followed by valproate. 
 A reduction in the differences in cost between treatment with levetiracetam and the 
comparator drugs was observed on inclusion of the other health systems costs. 
 




Lamotrigine was found to be the most cost-effective and appropriate treatment option for 
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cost-effective in the treatment of newly diagnosed epilepsy in the South African public health 
sector. These findings agree with those from the study conducted for the National Institute for 
Health and Clinical Excellence (NICE) in the United Kingdom which concluded that use of 
levetiracetam as first line treatment for epilepsy was not cost-effective. For levetiracetam to be 
more cost-effective than lamotrigine, a price reduction of 93% is required, which is not likely 
to occur in the South African context as levetiracetam is already obtained by the government 
on tender. The use of lamotrigine as first line epilepsy treatment is recommended by both NICE 
and the Scottish Intercollegiate Guidelines Network (SIGN). 
Other considerations in maximising treatment outcomes after the introduction of cost-effective 
treatment include patient adherence and proper use of medication. This is especially important 
in the South African context, specifically in rural areas, where Western medicines are often 
mixed with traditional medicines (10). Treatment outcomes and treatment seeking behaviour 
is also inevitably affected by societal views on the disease (5). 
This study did not include sub-group analysis, for example; the cost-effectiveness of 
levetiracetam in treating pregnant women, the elderly or patients who are HIV positive. Further 
research on these sub-groups is necessary to ensure appropriate treatment for all epileptics. 
Challenges faced in the conducting of this study include access to South African specific data 
on the epidemiology of epilepsy. To improve the accuracy of future studies, there is need to 
improve information databases. 
POLICY RECOMMENDATIONS 
 






 Using lamotrigine as the primary first line treatment for epilepsy. 
 Provision of training to healthcare professionals on epilepsy diagnosis along with the 
proper use and titration of lamotrigine. 
 Provision of patient education alongside treatment to ensure treatment adherence and 
maximize treatment outcomes. 
 Introduction of an educational program on epilepsy in rural areas through community 
health workers to reduce the stigma associated with epilepsy and encourage epileptics 
to seek treatment.  
 Provision of education to the families of epileptics on how to deal with seizures and 
minimize the chances of a seizure related death. 
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